index

A
AACPI, 2
Abdominal pain
cancer-related, 534
Crohn's disease and, 597–598
Absorption, drug
elderly and, 687, 688
intraspinal local anesthetics and, 228
of opioid, 167–169, 168f
rectal, 204
Abstinence syndrome, 609, 616–617
nalbuphine causing, 614
Abuse
elder, 706
substance, 428–462; see also Addiction
Accountability for pain management, 3–4, 730, 733
Accreditation, 730, 733
Acetaminophen
antihistamines with, 150
aspirin with, 148–149
breast feeding and, 623
caffeine with, 316
clinical considerations for, 108–110
combination drugs with, 116–117, 134
definition of, 130
dosage of, 139f
for child, 143f
frequency, 139–140f, 140–141
guidelines for, 142
opioid equivalent, 133f
titration of, 141
elderly and, 690
equianalgesic dosage of, 133f
hemophilia and, 599
indications for, 131–134
infant and, 653–654
mechanism of action of, 130
nonprescription formulations of, 148f

Acetaminophen—cont'd
nonsteroidal antiinflammatory drugs versus, 104
overdose of, 151–152
pregnancy and, 611, 613
preparations of, 148f
as rectal suppository, 150f
safety of, 110
side effects of, 134–136
tension headache and, 558
Acetic acid derivative, 139f
Acetylsalicylic acid; see also Aspirin
infant and, 654
migraine and, 554f
Acquired immunodeficiency syndrome, 564–568, 566f
peripheral neuropathy and, 576
Action potential
definition of, 16
nociception and, 19f
transduction of pain and, 18
Action stage of drug treatment, 448
Action sites, analgesic, 106–107f
Acupuncture for fibromyalgia, 549
Acute pain model
adaptation versus, 43–45
correction of, 45–46
Acute pain services, 11
Acute versus chronic pain, 493–494; see also Pain entries
Addiction
challenges of, 462
definition of, 36, 50–51, 162, 429, 433–436
discussing with patient and family, 275–276f
drugs of abuse and, 432–433, 432f, 433f
elderly and, 705–706
family’s fear of, 10
infant and, 631
as label, 51, 53–54
memory of pain and, 30
misconceptions about, 52–53f, 276f, 430f, 439–440
misinterpretation of, 173–174
models of, 431–432, 431f

t after a page number indicates a table, box, or form; f after a page number indicates an illustration.
Addiction—cont’d
  to opioid, 173–174
  undertreatment of pain and, 9
  pain management in, 450–462, 455, 460
  chronic pain and, 461–462, 477
  clinical principles in, 453–454
  inpatient, 454–456, 461
  naltrexone and, 460–461
  outpatient, 456, 458
  overlap between, 452–453
  recovery from addiction and, 459–460
  patient information about, 275–276
  patient placement and, 451, 451
  phenomenology of, 436–440
  response documentation, 459
  treatment of, 440–450
    characteristics of, 441
    cognitive-behavioral, 445–446
    commonalties in, 446
    detoxification and, 441–442
    drugs used in, 442–445
    referral for, 446–450
    residential, 446
    twelve-step, 442–443
    written agreement for, 754–755
Adenocard; see Adenosine
Adenoscan; see Adenosine
Adenosine, 339
Adenosine triphosphate, 22
Adhesive, tissue, 395
Adjuvant analgesics, 105, 302–353
  for acute pain, 335–340
  alcohol as, 334–335
  alpha2-adrenergic agonists as, 313–314
  antidepressants as, 306–311, 306
    see also Antidepressants
  antihistamines as, 334
  benzodiazepines as; see Benzodiazepine
  breast feeding and, 623–624
  caffeine as, 315–316
  cannabinoids as, 334
  in children, 340, 341
  for chronic pain
    bone, 324–326, 325
    classes of, 305
    lancinating, 320–324
    multipurpose drugs for, 306–317
    musculoskeletal, 327–328, 327
    neuropathic, 317–320, 317
    328–332
  classifications, 304
    major, 305
  clinical considerations for, 112–113
  cocaine as, 316
  combination analgesics with, 116
  comparison of, 114, 115
  corticosteroids as, 311–313
  definition of, 104, 162
  dextroamphetamine as, 314–315
  dosage of, 341–344
  elderly and, 695–698
  examples of, 109
Adjuvant analgesics—cont’d
  general considerations in, 303–306
  guidelines for use, 342–344
  indications for, 316–317
  local anesthetics as, 316
  for malignant bone pain, 325
  for malignant bowel obstruction, 327
  methylphenidate as, 314–315
  misconceptions about, 303
  neuroleptics as, 316–317, 332–334
  NMDA receptor blockers as, 317
  pain mechanism affected by, 108
  patient information about, 340, 345–353
  pediatric dosing, 341
  pregnancy and, 614–615
  reflex sympathetic dystrophy and, 583
  temporomandibular dysfunction and, 590
  titration of, 122
Administration of analgesic; see Route of administration;
  specific route
Administrative rules on pain management, 738
Admission assessment of pain, 58–59, 59
Adrenocorticotropic hormone, pain and, 2
Adverse drug effects
  elderly and, 689
  fetal, 621
  HIV and, 566–567
  infant and, 655
Advil; see Ibuprofen
Affereent neuron, 16
Age
  elderly and, 674–706; see also Elderly patient
  infant and, 629–669; see also Infant
  opioid and, 192
  pain assessment and, 57
  shingles and, 561
Agency for Health Care Policy and Research
  clinical practice guidelines of, 7, 43–44
  education of clinicians and, 89
  low back pain and, 600
  nondrug pain treatment and, 423
  patient education materials of, 274
  quality improvement and, 713
  undertreatment of pain and, 2
Aggregation, platelet, 138, 144
Agitation in alcohol withdrawal, 457
Agonist, mu; see Mu agonist
Agnost-agonist-antagonist
  buprenorphine, 188
  butorphanol, 188–189
  characteristics of, 188–190
  clinical considerations for, 112
  combinations analgesics with, 116
  comparison of, 114
  definition of, 162, 363
  dezocine, 189
  examples of, 109
  intranasal administration of, 203
  labor and delivery and, 618
Agonist-antagonist—cont’d
mild pain and, 191
misconceptions about, 163t
mu agonist with, 112
nalbuphine, 189
opioid receptor sites and, 166
pentazocine, 189–190
pruritus and, 265–266
Agreement, written, 751–752
AHCPR; see Agency for Health Care Policy and Research
AIDS, 564–568, 566t
peripheral neuropathy and, 576
Alcohol addiction, 432
CAGE questionnaire about, 705
elderly and, 705–706
pharmacologic effects and, 432
psychiatric disorders with, 436–437, 436t
, 437t
treatment of, 445
withdrawal assessment and, 457t
Alcohol as adjuvant analgesic, 334–335
Alcoholics Anonymous, 442–443, 442t
Aleve; see Naproxen
Algorithm for infant care, 662–663
Alka-Seltzer, 148t
Allergy
aspirin, 144
intraspinal local anesthetics and, 228
nonsteroidal antiinflammatory drug and, 110
opioids and, 193
Allodynia, 302
definition of, 16
herpes zoster and, 562
Alpha2-adrenergic agonist
clonidine; see Clonidine
types of, 305t
indications and dosages of, 342t
neuropathic pain and, 321t
Alpha1-blocker for postmastectomy pain, 604
Alzheimer’s disease, 675
Ambulatory surgery, 145
Amerge; see Naratriptan
Americaine; see Benzocaine
American Academy of Head, Facial and Neck Pain, and TMJ Orthopedics, 516
American Academy of Hospice and Palliative Medicine, 13
American Academy of Pain Medicine, 11
American Academy of Physical Medicine and Rehabilitation, 516
American Alliance of Cancer Pain Initiatives, 2, 11
American Amputee Foundation, 516
American Board of Internal Medicine, 6
American Board of Pain Medicine, 516
American Burn Association, 527
American Chiropractic Association, 516
American Chronic Pain Association, 516
American College of Emergency Physicians
clinical practice guidelines of, 7
unknown cause of pain and, 47
American Foundation for Pain Research, 516
American Pain Society, 516–517
acute pain model and, 43–44
American Pain Society—cont’d
clinical practice guidelines of, 7
definition of pain and, 16
education of clinicians and, 89
founding of, 11
home page, 747t
pain care committee and, 715
patient-controlled analgesia, 249
quality improvement and, 713
unknown cause of pain and, 47
web site of, 747t
American Society of Addiction Medicine, 461
American Society of Clinical Oncology, 6
American Society of Pain Management Nurses, 517
certification and, 11, 13
founding of, 11
placebo and, 55–56
Amethocaine, 376
Amitriptyline, 305t, 306t
as adjuvant analgesic, 306
dosage of, 343t
elderly and, 696–697, 699t
fibromyalgia and, 548
indications for, 310
tension headache and, 555t
Amphetamine, 193
Amputation, 257–258
pain after, 603–604
phantom limb pain after
in elderly, 694
previous acute pain and, 30–31
Anacin, 149t
Anafranil; see Clomipramine
Analgesics; see also Analgesics
balanced; see Balanced analgesia
conscious, 382–384t
epidural; see Epidural analgesia
intraspinal; see Intraspinal analgesia
masking diagnostic information with, 47
optimization of, 122–123
overview of, 103–128
patient-controlled; see Patient-controlled analgesia
preemptive; see Preemptive analgesia
principles of, 121–123
procedures requiring, 365t
Analgesics
action sites, 106–107f
adjuvant; see Adjuvant analgesic
Andrew–Robert survey and, 38t, 40
assessment of, 38t
combined; see Combination analgesics
comparing, 105t, 116t
differential diagnosis, 172t
formulary guide, 737t
by infusion; see also Infusion
flow sheet for, 79–80t, 83–86t
groups and subgroups, 105t, 109t
comparisons of, 114t
Analgesics—cont’d
  list of, 125t
  nonopioid, 129–159; see also Acetaminophen; Nonsteroidal antinflammatory drug
  nonprescription, 148–149t
  nurses response to survey, 40t
  opioid; see Opioid analgesic
  pregnancy misconceptions, 610t
  patient controlled, 754t
  outpatient opioids, 755t
  topical, 331t; see also Topical agents
  use of, 38t
during pregnancy, childbirth, postpartum, and breast feeding, 608–625
Analgesic ceiling
definition of, 104, 130, 162, 363
  elderly and, 690
Analgesic groups, 104–128
Analgesic ladder, WHO, 115–119, 117f
Anaprox; see Naproxen
“Andrew-Robert” survey, 38t, 40t
  nurses’ expectations about pain and, 44
Anecdotal evidence, 302
Anemia, sickle cell, 585–588
Anesthesia
  action sites, 319f
  circumcision and, 636–637
  epidural; see Epidural analgesia
  general, 386–389, 387t
  local; see Local anesthetic
  low back pain and, 600
  nerve block records and, 511–512t
Aneurysm, aortic, 26
Angiography, back pain from, 391
Animal, companion, for relaxation, 421
Ankylosing spondylitis, 595–596
Antacid
  misconceptions about, 131t
  prevention of ulcers and, 137
Antagonist, 162
  opioid, inappropriate use, 269
Antenatal period, 609
Anterior deltoid trigger point, 571f
Antiarrhythmic agent for temporomandibular dysfunction, 590
Anticholinergic agent
  antidepressants as, 308
  elderly and, 695, 697
  malignant bowel obstruction and, 327, 327t
  opioids and, 193
Anticonvulsants
  action sites, 319f
  adverse effects of, 322–324
  breast feeding and, 624
  carbamazepine and, 321
  clonazepam and, 322
  dosage for, 324
  elderly and, 697
  examples of, 305t
  gabapentin and, 322
  herpes zoster and, 562
  indications and dosages of, 342t
  lamotrigine and, 322
  mechanism of, 322
  migraine and, 555t
  neuropathic pain and, 321t
  peripheral neuropathy and, 578
  phenytoin and, 321–322
  pregnancy and, 615
  temporomandibular dysfunction and, 590
  valproic acid and, 322
Antidepressants
  action sites of, 309f
  analgesics, 306t
    adjuvant, 306t
  breastfeeding and, 623–624
  for child, 341t
  for chronic pain, 306–311
  adverse effects of, 308–310
  amitriptyline and, 306
  clomipramine and, 307
  desipramine and, 307
  dosage of, 310–311
  doxepin and, 307
  imipramine and, 306–307
  indications for, 310
  mechanism of action of, 308
  monitoring of, 311
  newer, 307
  nortriptyline and, 307
  selection of, 310
  elderly and, 696–697, 699t
  fibromyalgia and, 548
  herpes zoster and, 562
  misconceptions about, 303t
  neuropathic pain and, 317, 317t, 321t
  osteoporosis and, 575
  pregnancy and, 614–615
  temporomandibular dysfunction and, 590
  tricyclic
    in elderly, 696–697
    examples of, 306
    indications and dosages of, 343t
    modulation of pain and, 23
    opioids and, 193
    peripheral neuropathy and, 578
    postmastectomy pain and, 604
    tension headache and, 555t
Antidiuretic hormone, 24
Antihistamine
  as adjuvant analgesic, 334
  elderly and, 695
  nonopioids with, 150
  opioids and, 193
Antinflammatory drug, nonsteroidal, 129–159; see also Non-steroidal antiinflammatory drug
Antiparkinsonian drug, 193
Antipyretic, 144; see also Aspirin; Nonsteroidal antiinflammatory drug
Antisocial personality, 436
Antiviral agent
herpes zoster and, 563
HIV and, 565
Anxiety
alcohol addiction and, 436
withdrawal from, 457
burn injury and, 529f
as cause of pain, 48–49
chronic pain and, 500
definition of, 468
reducing, 390f
Aortic aneurysm, 26
APAP, 138f, 148f, 150f
Aphthous ulcer in HIV, 566–567
Appliance for temporomandibular dysfunction, 590
Arachnoiditis, 596
Around the clock dosing, 175
cognitively impaired elderly and, 704
rescue dose and, 244–246
Arteritis, temporal, 695–696
Artery, coronary, bypass of, 694
Arthritis, 149f
Arthritis, 523–527, 524f, 525f
alternative treatment for, 690f
in child, 143f
Arthritis Foundation Aspirin Free, 148f
Arthropan; see Choline salicylate
Artificial saliva, 602
ASA; see Aspirin
Aseptic necrosis, 539
Aspirin
acetaminophen with, 148–149
allergy or intolerance to, 144
bleeding and, 135, 138
buffered, 149
dosage of, 139f
for child, 143f
equianalgesic dosage of, 133f
indications for, 131
infant and, 654
nonprescription formulations of, 148–149f
overdose of, 150–151, 152
pediatric dosage of, 143f
renal function and, 136
topical, 332
Aspirin Free Maximum Strength, 148f
Aspirin Free Pain Relief, 148f
Assessment, 36–99, 123
addiction and, 461
admission, 58–59, 59f
of analgesic history, 124f, 125f
arachnoiditis and, 596
behavioral responses, 43–45, 95f
challenges in, 89, 92–99
complexities of, 36–39
Crohn’s disease and, 598
elderly and, 686–687
epidural anesthesia, 230–231f
Assessment—cont’d
failure to attain, 36–38
of headache, 550, 552
herpes zoster and, 562
initial, 58–62, 60f, 61f
institutional needs, 724–726
lack of accountability for pain and, 3–4
low back pain and, 599–600
misconceptions affecting, 37f, 39–58
addiction and, 50–54
authority about pain and, 39–42
clinician’s expectations and, 44–46
implications of, 56–58
know versus unknown cause of pain and, 46–50
pain threshold and, 42
pain tolerance and, 42–43
placebos and, 54–56
responses to pain and, 43–44
multiple sclerosis and, 602
myofascial pain syndrome and, 569–570
ongoing, 97f
pain management and, 720–730
physiologic responses, 43–45, 95f
postmastectomy pain and, 604
postthoracotomy pain and, 606
of procedural pain, 366–367
spinal cord injury and, 607
tools for, 58–89
breakthrough pain and, 75, 78
communication strategies and, 84, 86, 89
flow sheets and, 78–84, 85
initial, 59–62, 60–61f, 60–61f
neuropathic pain scale, 75, 76–77
nursing admission, 58–59
pain rating scales and, 62–75
teaching to use, 67–75, 74f
Association for Applied Psychophysiology and Biofeedback, 517
ATC dosing, 175
cognitively impaired elderly and, 704
rescue dose and, 244–246
Atenolol, migraine and, 555f
Atherosclerosis, 696
Ativan; see Lorazepam
Atraumatic suturing, 395
Atrophic stage of reflex sympathetic dystrophy, 582
Audit, medical record pain management, 727
Auditory disturbance in alcohol withdrawal, 457
Aura, migraine, 552
Aventyl; see Nortriptyline
B
Back pain, 599–600
alternative treatment for, 690f
angiography causing, 391
arachnoiditis and, 596
chronic, 473–474
failed back syndrome and, 496
osteoporosis causing, 573
pregnancy causing, 615–616
Back pain—cont’d
psychiatric setting and, 475–476
Background pain with burn injury, 529t
Baclofen, 305t
indications and dosages of, 343t
modulation of pain and, 23
multiple sclerosis and, 603
overview of, 324
Bacteriostatic saline, 370
Balanced analgesia
characteristics of, 174–175
clinical application of, 120, 120t
concept of, 174–175
definition of, 162
explanation of, 119–121
perioperative, 144–145
Barbiturate for procedural analgesia, 381, 386
Barriers
to assessment, 37t
to drug treatment, 449
to pain management improvement, 714
questionnaire, 93t
to treatment, 37t
Barriers Questionnaire, 89, 92, 93
Bathing, contrast, 411
Bayer Select Aspirin-Free Headache, 149t
BC preparation, 149t
Beck Depression Inventory, 519
Bedrest, osteoporosis and, 574
Behaviors
addictive; see Addiction
drug-seeking, 52–53t, 429
addiction versus, 434–435
elderly and, 686–687
indicative of pain, 95t
memory of pain and, 30
pain
description of, 95
expectations about, 44–46
impaired communication and, 95, 98
in infant, 633–634, 633t, 649
Behavioral method of treatment
drug abuse and, 442t, 445–446
infant and, 658–659
for procedural pain management, 389–390
Benzocaine
for procedural pain, 369t
topical, 371–372
Benzodiazepines—cont’d
as nonanalgesic, 113
opioid with, 499
pregnancy and, 615
procedural analgesia with, 380, 381
misconceptions about, 364t
for procedural sedation, 385–386t
Beta-blocker for migraine, 555t, 556
Bethanechol
elderly and, 697
side effects of, 308
Bier block, 584
Biliary spasm, opioids causing, 265
Bill of rights for patients with pain, 13
Binding
opioid receptor sites and, 108
protein, in elderly, 688
Bioavailability
definition of, 162
intraspinal anesthesia and, 220–222
of opioids, 167–169
Biphosphonate, 325, 325t
Bipolar disorder, 436
Birth; see Labor and delivery
Black market for drugs, 438–439
Bleeding
angiography and, 391
nonsteroidal antiinflammatory drugs causing, 138, 144
gastrointestinal, 136, 137, 145–146
at operative site, 145–146
perioperative, 145–146
Bleeding time
aspirin and, 135, 137
nonsteroidal antiinflammatory drugs and, 138, 145
Block
nerve; see Nerve block
paravertebral sympathetic ganglion, 583–584
Blood disorder
hemophilia and, 598–599
sickle cell disease, 585–588
Blood
–brain barrier, 162
patch, 232
vessels, in migraine, 553
Board, state medical, 9–10
Board of Registered Nursing, 6
Body surface area in burn injury, 527
Boluses, 211
cesarean section and, 622–623
elderly and, 693
intraspinal, 220, 221
intermittent, 221t
titration of dose and, 247
Bones
aseptic necrosis of, 539
cancer-related pain in, 109t, 113, 324–326, 325t, 533t
indomethacin affecting formation of, 147
malignant, 325t
osteoporosis and, 572–576
Bowel obstruction, 326–327, 327t
Brace for osteoporosis, 575
Brachial plexus
  cancer-related pain and, 535
t  radiation fibrosis of, 540
Brain
  addiction and, 432
  dopamine pathway in, 434
  migraine and, 553
  opioid receptors in, 165–166
  pain perception and, 22
Brand names of nonopioid drugs, 138
Braxton Hicks contraction, 616
Breakthrough pain
  burn injury causing, 529
  fentanyl for, 202–203
  opioids for, 175
  rating scale for, 75, 78
  selection of analgesic for, 121
Breast
  postmastectomy pain and, 604
  postpartum pain and, 622
Breast cancer, 532
  age and, 678
Breast feeding, 610, 623–624
  acetaminophen during, 623
  adjuvant analgesics during, 623–624
  nonsteroidal antiinflammatory drugs during, 142
  opioid analgesics during, 623
Breathing technique
  labor and delivery and, 617
  for relaxation, 419–420
Brief Pain Inventory, 61, 62
  cultural differences and, 98
Bromo-Seltzer, 148
Brompton’s cocktail, 316
Buccal administration of opioids, 195, 201
Buffered aspirin, 149
  gastric injury and, 137
Bupivacaine
  breast feeding and, 623
  dosage of, 369
  elderly and, 694
  injectable, 368
  intraspinal, 228
  labor and delivery and, 618, 620
  for procedural pain, 369
Buprenorphine
  characteristics of, 188
  equianalgesic doses of, 242
  labor and delivery and, 112, 618
  opioid receptor sites and, 166
Butorphanol, 306
Butorphanol nasal spray, 112
Bypass surgery, coronary artery, 694
C
Cafergot; see Ergotamine
Caffeine
  as adjuvant analgesic, 315–316
  beverages containing, 151
  breast feeding and, 624
  indications and dosages of, 344
  nonsteroidal antiinflammatory drugs with, 149–150, 149
CAGE questionnaire, 705
Calan; see Verapamil
Calcitonin
  bone pain and, 325, 325
  indications and dosages of, 344
  neuropathic pain and, 321, 330
  osteoporosis and, 574
Calcium-channel blocker
  cluster headache and, 556
  migraine and, 555
Cancer pain initiatives, 11
Cancer-related pain, 531–543, 532
  adjuvant analgesics for, 109, 113
  bone pain and, 324–326, 325
  bowel obstruction and, 326–327, 327
  Brompton’s cocktail for, 316
  characteristics of, 532–537
  cost of, 4
  death statistics, 532
  description of, 531–532
  elderly and, 678–679, 678
  family’s attitude toward, 10
  intraspinal sufentanil for, 227
  intravenous opioid for, 211
  management of, 539–542
  mucositis and, 601–602
  musculoskeletal tumor, 533
  neuropathic, 535–536
  noncancer pain versus, 47–48
  nondrug treatment of, 401, 405
  oxycodone for, 243
  patient-controlled analgesia for, 249
  postchemotherapy, 538–539
  postradiation, 540
  postsurgical, 537
  procedures and treatment causing, 537–540, 537–540
  rescue analgesia for, 247–248
  resources for, 542
  sites of, 532
  spinal cord compression as, 339–340
  stomal administration of opioid in, 205–206
  viscera involvement, 534
  WHO analgesic ladder for, 115–119
Cannabinoid, 334
Capaisin, 305
  adverse effects of, 332
Carbamazepine, 305
  adverse effects of, 322–323
  for child, 341
Carbamazepine—cont’d
indications and dosages of, 342t
neuropathic pain and, 321t
overview of, 321
Carcinoma; see Cancer-related pain
Cardiac disease in elderly, 698
Cardiac surgery
in elderly, 678t
in infant, 662
Cardiotoxicity of antidepressants, 309–310
Cardiovascular system
antidepressants in elderly and, 697
Ehlers-Danlos syndrome and, 543
harmful effects of pain on, 25–26
local anesthetic in elderly and, 698
Caregivers
for elderly, 684, 685t, 686
report of patient’s pain, 39–40
Carisoprodol, 305t, 327, 328
elderly and, 700
musculoskeletal pain and, 327t
Case report, 302
Catabolism, 16
Catheters
epidural, 218t
location of, 248
patient education about, 366
removal of, 82, 236t
spinal, 214–216, 232–233
intraspinal displacement and migration, 233t
urethral, 372
Catheritization, atraumatic urethral, 372t
Causalgia, 581–584
Cause and effect diagram, 722f–723f
Ceftriaxone with lidocaine, 371
Ceiling analgesia, 104, 162
for acetaminophen, 141
definition of, 130
elderly and, 690
for opioid-nonopioid combination drugs, 134
Celiac plexus neurolytic block for pancreatitis, 581
Cell, natural killer, 29
Central nervous system; see also Brain; Neurologic disorder
nonsteroidal antiinflammatory drugs affecting, 138
opioid receptors in, 165–166
opioid withdrawal in infant and, 632
Centrally generated pain
classification of, 19t
definition of, 16
Cerebrospinal fluid
dural puncture and, 232
intraspinal anesthesia and, 214, 221–222
Certification of pain specialists, 11–12
Cervical trigger point, 571f
Cervical vertebral tumor, 533t, 536t
Cesarean section, 621
clonidine for, 336
pain after, 622–623
Cessation of opioid therapy, 270–271
Cetacaine, 371–372
Chart
equianalgesic, for opioids, 174, 240–243
graphic vital sign, 735
Checklist, patient teaching, 273
Chemical dependence, 429
Chemical irritation, wound pain and, 592–593
Chemotherapy, 538t–539t
Chest surgery
in elderly, 678t
pain of, 605–606
Chest trauma, 26
Chest wall tumor, 533t
Child
adjuvant analgesics for, 340
clonidine for, 336
dosage of, 341t
aspirin avoided in, 143t
bupivacaine for, 237–238, 368
cancer-related pain in, 537
conscious sedation in, 382–385t
epidural analgesia in, 236–239
local anesthetic toxicity in, 368
nondrug pain treatment for, 421, 422
nonsteroidal antiinflammatory drug for, 142–144, 143t
opioid for
intraplural, 211, 213
rectal administration of, 205
pain behavior in, 46
patient-controlled analgesia in, 253, 255t
rectal administration in, 150t
refrigerant spray for, 377
topical anesthetic for, 372
Childbirth, 617–623; see also Labor and delivery
Chloral hydrate
infant and, 655
procedural analgesia with, 386
Chlordiazepoxide, 698, 699t
Chloroform in topical agent, 332
Chlorpromazine
for migraine, 554t
procedural analgesia with, 380
Chlorzoxazone, 305t, 700
musculoskeletal pain and, 327t
Chocolate, caffeine in, 150
Choline magnesium trisalicylate
bleeding disorder and, 138, 144
dosage of, 139t
for child, 143t
patient information sheet on, 155–156
Choline salicylate
dosage of, 139t
equianalgesic, 133t
opioid equivalent, 133t
trade name of, 138t
Chronic fatigue immune deficiency syndrome, 597
Chronic fatigue syndrome, 597
Chronic illness problem inventory, 519
Chronic pain, 467–520, 490–505
acute care setting and, 473–475
acute pain versus, 493–494
addiction and, 461–462
treatment center for, 477
adjuvant analgesic for, 109t, 112–113
admission assessment and, 492–493
antidepressants for, 310
assessment of, 477–487
of bone, 109t, 113, 324–326, 325t, 533t
breakthrough, 175; see also Breakthrough pain
cancer-related; see Cancer-related pain
challenges of, 472–473
in child, 143t; see also Child
combination analgesics for, 116
cost of, 472
definition of, 17, 468, 471
drug management in, 494–499
education about, 494
everly and, 679
in infant, 640
intraspinal administration and, 219f
long-term planning in, 505
management techniques for, 505, 510
misconceptions about, 469–470
nerve blocks for, 510–513
nonmalignant
activity changes, 509f
anesthesia nerve block, 511–512t
differential blocks, 510t
examples, 472t
medication, 489t
opioid therapy, 498t
patient assessment, 486t
patient care, 491t
patient daily plan, 506t
patient future plan, 507t
patient questionnaire, 478–485t
psychiatric disorders, 476t
return visit survey, 508t
severity of, 509f
treatment, 489t
treatment goals, 488t
nonsteroidal antiinflammatory drugs for, 133–134, 138, 140, 142
opioid analgesics for, 492
written agreements about, 753–754
osteoporosis and, 574–575
placebos and, 492
polypharmacy in, 304
prevalence of, 471–472
previous acute pain and, 30
psychiatric settings and, 475–477
psychosocial considerations in, 499–503
referral for treatment of, 513, 516–520
rehabilitation and, 487–490, 503, 505
respect for individual and, 491–492
selection of analgesic for, 121
suicide risk and, 487
Cimetidine
elderly and, 699t

Cimetidine—cont’d
nonsteroidal antiinflammatory drugs and, 131t
ulcer prevention and, 137
Circumcision, 371, 636–639
EMLA for, 376
memory of pain in, 30
City of Hope Medical Center, 4–5, 274
Classic migraine, 552
Clearance, drug
of intraspinal local anesthetics, 228
of opioid, 169–170
Clinical pathway, 679–680, 738–739
Clinical practice guideline, 5, 7t
Clinical scoring system for pain in infant, 641
Clinical trial, types of, 302
Clinician; see Health care professional
Clofibrate, 325
Clonipramine, 305t, 306t
as adjuvant analgesic, 307
indications and dosages of, 343t
Clonazepam, 305t
adverse effects of, 323
characteristics of, 335
indications and dosages of, 342t
as muscle relaxant, 327, 328
musculoskeletal pain and, 327t
neuropathic pain and, 321t
overview of, 322
Clonidine, 305t
for crescendo pain, 336
dosage of, 314, 342t
epidural, 229, 231, 315t
herpes zoster and, 562
indications for, 314, 342t
intraspinal, 229, 231
mechanism of, 313–314
neuropathic pain and, 321t
peripheral neuropathy and, 579
for regional anesthesia, 337t
Clorazepate, 698
Cluster headache, 558–559, 558f
drugs for, 555t–556
Coagulation, 598–599
nonsteroidal antiinflammatory drugs and, 135; see also
Bleeding
vascular surgery and, 25–26
Cocaine
addiction to, 432t, 433
as adjuvant analgesic, 316
in topical mixtures, 373
Cocktail, Brompton's, 316
Codeine
characteristics of, 179t, 181
in combination drug, 117, 134
equianalgesic dosage of, 133t, 241t
infant and, 655
nebulized, 203
pregnancy and, 614
transdermal fentanyl and, 209t
Coerced drug treatment, 446
Cognitive impairment
effects of pain and, 28–29
ever elderly and, 675, 686–687, 701–705
onsteroidal antiinflammatory drugs and, 135
pain assessment and, 94
Cognitive-behavioral intervention
cancer-related pain and, 541
chronic pain and, 500–501
drug abuse and, 442t, 445–446
procedural pain management and, 389–390
Cold, 406–411, 409
arthritis and, 526
herpes zoster and, 562
injection site pain and, 394–395
pain reduction with, 390
patient and, 410t, 411t
Colon cancer, 532t
age and, 678t
Combination analgesics
brands and dosages, 149t
chronic pain and, 496
epidural, 694
examples of, 116–117
ketamine and morphine, 338
labor and delivery and, 618
mild pain and, 191
misconceptions about, 105t
onsteroidal antiinflammatory, 132, 149t
opioid and nonopioid, 134
prevention of NSAID-induced ulcers and, 137
procedural analgesia with, 380
rationale for, 109–110, 115
WHO analgesic ladder and, 115–119
Combined spinal-epidural anesthesia, 231
COMFORT Scale, 649, 650
Commission on Accreditation of Rehabilitation Facilities, 517
Committee, pain care, 713, 715–737; see also Pain care committee
Committee on Pain of the American Society of Addiction Medicine, 461
Communication
aids to, 128
chronic pain treatment and, 488, 490
impaired, 92, 94–95, 98–99
nurse-physician, 92t
pain assessment and, 84, 86, 89
Companion animal for relaxation, 421
Compazine; see Prochlorperazine
Complex regional pain syndrome, 581–584
Compliance
opioids and, 193–194
patient education for, 123, 124
Compression, spinal cord
cancer-related, 539
corticosteroids for, 312, 313, 339–340
Confusion
dementia versus, 704t
ever elderly and, 675, 701–705
Conscious sedation, 382–385t
Consent, informed, 365
Constipation
burn injury and, 529t
ever elderly and, 695
antidepressants and, 697
opioids causing, 262t
Containment of infant, 659
Contemplation stage of drug treatment, 447t, 448
Contingency-based drug therapy, 446
Continuous dysesthesia, 302
adjuvant analgesics for, 317
Continuous infusion, 244; see also Infusion intraspinal, 220
in opioid naive patient, 250–251
Continuous quality improvement, 713–715; see also Quality improvement
Contract
definition of, 751–752
for opioid use, 499
Contraction
Braxton Hicks, 616
opioid affecting, 619
postpartum, 622
Contrast bathing, 411
Controlled study, 302
Controlled-release formulation in rescue analgesia, 121
Conversion chart, equianalgesic; see Equianalgesic dosage
Cope, 149t
Coping response, 404–405
addiction and, 438
chronic pain and, 501–503
Coping Strategies Questionnaire, 519
Cord, spinal; see Spinal cord
Coronary artery bypass surgery, 694
Corticosteroid
as adjuvant analgesic, 311–313
for bone pain, 325t, 326
breast feeding and, 624
cancer-related pain and, 538t, 541
cluster headache and, 556t
elderly and, 697–698
examples of, 305t
fibromyalgia and, 549
malignant bowel obstruction and, 327, 327t
migraine and, 555t
pregnancy and, 615
respiratory effects and, 26
transduction of pain and, 18
Cost
of chronic pain, 471–472
of drug treatment, 441f
of nonsteroidal antiinflammatory drugs, 141
of opioids, 194
of unrelieved pain, 4
Counterirritation, 390
COX-1, 130
COX-2, 130
Cramping, fibromyalgia and, 547–548
Cream, EMLA; see EMLA
Creatinine clearance, 170t
Crescendo pain, 335–340
CRIES neonatal pain scale, 642, 644f, 650
Criminal model of addiction, 431, 438–439
Crisis, sickle cell, 585–588
Criterion, 712
Critically ill infant, 661
Crohn’s and Colitis Foundation of America, 517
Crohn’s disease, 597–598
Cross-tolerance of opioids, 172
methadone and, 185–186
Crying by infant
opioid withdrawal and, 632
pain and, 633, 633f
CSEA; see Combined spinal–epidural anesthesia
Cultural factors in pain assessment, 57, 98–99
Cumulation of opioid, 169–170
Curriculum guidelines for pain management, 5
Cushingoid appearance, 312
Cutaneous stimulation, 390, 405–412
heat and cold for, 406–411
sites for, 406f
vibration as, 411–412
Cyclandelate, 699t
Cyclobenzaprine, 305t
elderly and, 700
fibromyalgia and, 548
as muscle relaxant, 327, 328
musculoskeletal pain and, 327t
Cyclone for mucositis, 602
Cyclooxygenase, 132f
nonsteroidal antiinflammatory drugs and, 130
Cyclooxygenase inhibitor, 130, 132f

D
Dalgan; see Dezocine
Dalmane; see Flurazepam
Darvon; see Propoxyphene
Data
definition of, 712
pain management, 720–730
qualify improvement, 721t
Deafferentation pain, 19t, 302
Death, pain causing, 17
Debilitation, 675, 700–701
Decadron; see Dexamethasone
Deep breathing, 419–420
Delirium
definition of, 675
opioids causing, 263t
meperidine, 183–184
Delivery, drug; see Route of administration; specific route
Delta opioid receptor site, 166
Delta-9-tetrahydrocannabinol, 334
Deltoid injection site, 394f
Deltoid trigger point, 571f
Dementia, 687
aging and, 702
confusion versus, 704t
definition of, 675
Demerol; see Meperidine
Depakone; see Divalproex; Valproic acid
Depakote; see Divalproex; Valproic acid
Dependence
addiction versus, 434
definition of, 50, 162, 429
HIV and, 567
in infant, 631
psychologic, 50, 173–174
substance, 429
Depolarization
definition of, 16
transduction of pain and, 18
Depression
alcohol addiction and, 436
as cause of pain, 48–49
chronic pain and, 499
definition of, 468
respiratory; see Respiratory depression
Dermal anesthesia, iontophoresis for, 377–378
Dermatomes, 217f
definition of, 363
herpes zoster and, 562
intraspinal anesthesia and, 221–222
Desipramine, 305t, 306t
as adjuvant analgesic, 307
breast feeding and, 623–624
for child, 341t
dosage of, 343t
indications for, 310, 343t
patient education about, 346–347t
Desyrel; see Trazodone
Determination stage of drug treatment, 448
Detoxification, 441–442
alcohol, 458
opioid, 459t
protocols, 456t, 458t, 459t
Dexamethasone, 305t
cluster headache and, 556t
high- and low-dose, 313
indications and dosages of, 343t
migraine and, 555t
spinal cord compression and, 339–340
Dexedrine; see Dextroamphetamine
Dexamethasone, 305t
Dextroamphetamine, 305t
as adjuvant analgesic, 314–315
for child, 341t
indications and dosages of, 344
morphine with, 339
Dextromethorphan, 305t
neuropathic pain and, 321t, 328–330
Dezocine
characteristics of, 189
equianalgesic doses of, 242t
DHE, migraine and, 554t
Diagnostic and Statistical Manual of Mental Disorders
drug dependence and, 435
psychogenic pain and, 49
substance abuse and, 435
Diarrhea in HIV infection, 567
Diary
headache, 551
pain relief, 200
Diatheses, bleeding, 138
Diazepam
elderly and, 698, 699t, 700
equisedating doses of, 656t
morphine with, 335
as muscle relaxant, 327, 328
musculoskeletal pain and, 327t
opioid with, 499
pregnancy and, 615
procedural analgesia and, 381, 385t
Diclofenac
cost of, 141, 142
dosage of, 139t
perioperative, 145–146
Diet in Crohn’s disease, 598
Diflunisal
antipyretic effect of, 144
cost of, 141, 142
dosage of, 139t
Dihydroergotamine
cluster headache and, 555t
medication withdrawal and, 559
migraine and, 554t
Dilantin; see Phenytoin
Dilaudid; see Hydromorphone
Diphenhydramine, 695
dosage of, 139t
Diprivan; see Propofol
Discharge from hospital
chronic pain and, 505
subcutaneous continuous infusion and, 212
Discomfort, reducing, 390t
Disease model of addiction, 431–432
Displacement, catheter, 233
Distraction, 412–417
benefits and limitations, 413t
for brief pain episodes, 414t
indications for, 413–414
labor and delivery and, 617
music for, 415t
picture descriptions for, 417t
procedural pain management and, 389–390
sing and tap rhythm for, 415t
strategies for, 414–417
Distress, reducing, 390t
Distress Scale for Ventilated Newborn Infants (DSVNI), 645–647, 646t, 650
new scoring system, 647t
Distribution of drug in elderly, 687, 688
Divalproex, 305t
indications and dosages of, 342t
Documentation
of infusion, 78–82
opioid and, 272
for outpatient, 82, 84
Dolobid; see Diflunisal
Dolophine; see Methadone
Dopamine pathway, 434f
Dopamine receptor, 333
Dorsal column stimulation, 584
Dorsogluteal injection site, 393f
Dosage
for anticonvulsant, 324
of antidepressant, 310–311
ATC dosing and, 175
ceiling; see Ceiling analgesia
for elderly, 695
epidural analgesia in child and, 238
equianalgesic
for infant, 655
for nonopioids, 133t
for opioids, 174, 240–243
phenobarbital and, 458
of local anesthetic, 320
of nonsteroidal antiinflammatory drugs
adverse effects and, 147–148
examples of, 139t
nurse-activated dosing and, 177
opioid
in opioid-naive patient, 250, 252t
rectal, 204–205
starting, 240–246
tolerance and, 171–173
patient-controlled analgesia and, 175–177; see also Patient-controlled analgesia
phenobarbital withdrawal equivalents, 458
PRN dosing and, 175
rescue dose and, 244–246
switching opioids and, 257
titrination of; see Titrination of dose
Double blind study, 302
Doxepin, 305t, 306t
as adjuvant analgesic, 307
indications and dosages of, 343t
tension headache and, 555t
D-Penicillamine, arthritis and, 526
DPT for procedural analgesia, 380
Dressing
epidural analgesia in child and, 237
wound, 593–594
Drug Enforcement Agency, 431
Drug tolerance, addiction versus, 432
Drug-receptor interaction, 165–166, 165f, 166t, 167f
Drugs
addictive classes, 432t
effects of abuse, 433t
Drug-seeking behavior, 50–52, 429
addiction versus, 434–435
Drug treatment
major models, 442t
twelve steps, 433t
Dry mouth, 308–309
DSM-IV, 36
DSVNI; see Distress Scale for Ventilated Newborn Infants
Duraclon; see Clonidine
Duragesic; see Fentanyl
Dural puncture, 232
Dyclone; see Dyclonine hydrochloride
Dyclonine hydrochloride, topical, 372
Dysesthesias
  continuous, 302, 317
  elderly and, 698
  lancinating, 321
  paroxysmal, 321
Dysesthetic pain syndrome, 606
Dyspnea, nebulized opioid and, 203
Dystocia, 609
Dystrophy, reflex sympathetic, 581–584, 582f

E
Education, patient
  acetaminophen and, 152
  about adjuvant analgesics, 346–353
  desipramine and, 346–347
  gabapentin and, 350–351
  mexiletine and, 352–353
  nortriptyline and, 348–349
  cancer-related pain and, 541
  chronic pain and, 494, 504, 506–507
  cold and heat and, 410
  materials, 274t
  for ”new” pain relievers, 345
  nondrug treatment and, 405
  nonsteroidal antiinflammatory drugs and, 152
  about opioid analgesic, 272–292
  addiction and, 275–276
  checklist for, 273
  fentanyl patch and, 277–278
  hydromorphone and, 279–280
  morphine and, 281–286
  oxycodone and, 287–290
  patient-controlled, 291–292
  resources for, 274
  pain care committee’s role in, 737
  pain management guidelines and, 123, 125, 126–127
  pain rating scales and, 67f, 74
  procedural pain management and, 365–366
  resource materials, 274t
  subcutaneous continuous infusion and, 212
Education, professional
  lack of, 4–5
  need for, 10
  pain care committee and, 730, 734, 736–737
  resources for, 6–8t
Efficacy
  definition of, 162
  of opioid, 170–171
  Ehlers-Danlos syndrome, 543–545
  distribution of chronic pain, 544f
Elavil; see Amitriptyline
Elderly patients, 674–706
  abuse of, 706
  acute pain in, 677–678
  adjuvant analgesics for, 695–698
  age classifications for, 677
  over age 100, 677f
  alcohol abuse in, 705–706
  assessment of, 686–687
  cancer-related pain in, 678–679
    caregiver role, 685t
    probability of invasive, 678t
  care settings for, 679–686
  chronic nonmalignant pain in, 679
  confusion, 704t
  cognitive impairment in, 701–705
  frail and debilitated, 700–701
  inappropriate medication use in, 692–693, 699–700, 699t
  mental state of, 703t
  memory impairment in, 705
  misconceptions about, 675–676t
  nondrug pain treatment in, 700
  nonmalignant conditions, 679t
  nonopioid analgesics for, 689–691
  nonsteroidal antiinflammatory drugs in adverse effects of, 689t
    alternative approaches, 690t
    central nervous system effects, 138
dosages, 142
  ketorolac, 146
  long-term use, 689t
  opioid analgesics for, 691–695
  physical abuse of, 706
  physiologic changes in, 687–689
  polypharmacy in, 698–699
  resources for, 684–685
  shingles and, 561–562
  surgery types, 678t
Electric stimulator for multiple sclerosis, 603
Electromyography for peripheral neuropathy, 577
Elimination of drug in elderly, 687, 688–689
Emergency department
  cancer patient and, 542
  chronic pain and, 473–474
  Ehlers-Danlos syndrome and, 545
  frequent use of, 51, 52, 53
  nondrug pain treatment and, 423
  sickle cell disease and, 587
Emergency treatment of respiratory depression in infant, 655
EMLA, 305t
  as adjuvant analgesic, 331
  adverse effects of, 332
  characteristics of, 373–377
  circumcision and, 637
  guidelines for, 375t
  for infant, 656–657, 664–665
  lidocaine, 375t
  prilocaine, 375t
  for procedural pain, 369t
Empathy in drug treatment, 449
Endocrine effects of pain, 23–25
Endogenous opioid
  composition and function of, 165
  definition of, 16
  modulation of pain and, 22–23
Endorphin, 17t, 164t
End-stage renal disease, 135–136
Enkephalin
  misconceptions about, 17t, 164t
  modulation of pain and, 22–23
Enteric-coated aspirin, 149
  gastric injury and, 137
Enterocolitis, necrotizing, 660
Enzyme
  metabolites and, 169
  nonsteroidal antiinflammatory drugs and, 130
Epidural analgesia, 213–239
  benefits of, 4
  bioavailability and, 220–222
  breast feeding and, 623
  cancer-related pain and, 541
  catheter for, 218f
    documentation about, 82
    location of, 248
    removal of, 236
  cesarean section and, 622–623
  characteristics of drugs for, 195t
  in child, 236–239
  clonidine for, 229, 231, 315, 336, 337f
  cognitive function and, 29
  combined, 231
  complications of, 232–236
  drug delivery and, 214–220
  effectiveness of, 25
  elderly and, 694
    cognitive impairment and, 701–702
  fentanyl and, 225
  gastrointestinal function and, 27–28
  guidelines for, 215
  hydromorphone and, 225–227
  hypercoagulability and, 25–26
  immune system and, 29
  ketamine for, 338
  labor and delivery and, 620
  local anesthetics and, 227–229
    muscle protein synthesis and, 25
  methadone and, 227
  misconceptions about, 214t
  morphine and, 222, 224–225
  in opioid-tolerant patient, 260–261
  pancreatitis and, 581
  patient education about, 366
  patient selection for, 215
  patient-controlled; see Patient-controlled analgesia
  pediatric dosage and care, 238t
  preemptive, 120–121
  respiratory effects and, 26
  side effect reduction, 254–255t
  spinal anatomy and, 213–214
  switching to intravenous analgesia from, 257–258
  unwanted effects of, 230–231
Epidural spinal cord compression, 539
Epinephrine
  local anesthetic toxicity and, 368
  modulation of pain and, 23
  in topical mixtures, 373, 374t
Episiotomy pain, 622
Equanil; see Meprobamate
Equianalgesic dosage
  for infant, 655
  for nonopioids, 133t
  for opioids, 174, 240–243, 241–243t
  phenobarbital and, 458
Ergotamine
  cluster headache and, 555t
  migraine and, 553, 554t
  withdrawal from, 559
Esophageal ulcer in HIV infection, 567
Estrogen replacement therapy, 575
Ethanol as adjuvant analgesic, 334–335
Ethical issues of placebo use, 55
Etodolac
  brand name of, 138
  cost of, 141
  dosage of, 140, 140t
  renal effects of, 138
ETOH, addiction to, 432
Eutectic mixture of local anesthetics; see EMLA
Excedrin Aspirin Free, 148t
Excedrin Extra Strength, 149t
Exercise
  chronic pain and, 503, 505
  fibromyalgia and, 549
  osteoporosis and, 575
Extrapyramidal effect of neuroleptics, 333
Extremely-low-birth-weight infant, 627
Extremity
  arthritis pain and, 523–525, 524f, 525t
  elderly and, 679t
  reflex sympathetic dystrophy and, 581–584
Eye
  anesthesia for, 372–373
  cluster headache and, 558
  Ehlers-Danlos syndrome and, 543
  surgery on, 678t
  zoster ophthalmicus and, 562
F
  Faces pain rating scale, 63, 64–65f, 67
    cultural differences and, 98
Facial Action Coding System, 641
Facial expression of pain in infant, 633f, 634f
Facial pain, temporomandibular, 588–592, 589f
Facility, pain
  classification of, 514
  increased numbers of, 10–11
Factitious disorder, 36
Failed back syndrome, 496
Family
  addiction and, 275–276t, 438
  as barrier to pain management, 10
  elderly and, 684, 686
  of infant, 668
  information for, 126–127t
  nondrug treatment and, 402
  pain rating scales and, 67f, 74
Family-controlled analgesia, 177
Fatigue, chronic, 597
Feedback in drug treatment, 449
Felbamate, 322
    adverse effects of, 323
Feldene; see Piroxicam
Femoral head, aseptic necrosis of, 539
Fenamate, 139
Fenoprofen, 139
Fentanyl
    absorption pathway, 207
    characteristics of, 181–182
    dosage, 209
    elderly and, 691
    cognitively impaired, 702
    equianalgesic doses of, 241
    infant and, 654, 655, 667
    intraspinal, 222, 223, 225
    labor and delivery and, 619
    mental status and, 267
    nebulized, 203
    for opioid-naive adult, 225
    oral transmucosal, 201–203, 202, 207, 209
    as rescue analgesic, 245, 245
    overdose of, 269
    patient information about, 277–278
    patient-controlled analgesia with
        in child, 255
        in opioid naive patient, 252
    preemptive analgesia with, 120–121
    pregnancy and, 614
    procedural analgesia with, 379
    rib fracture and, 26
    solubility of, 169
    switching from, 257–258
        to morphine, 208
    transdermal, 206–209, 207
Fetal heart rate, 621
Fetus
    drug effects on, 609–615
    pain in, 635–636
Fever in HIV infection, 567
Fiber, nerve, 577
Fibromyalgia, 545–550
    alternative treatment for, 690
    assessment of, 548
    classification criteria, 547
    description of, 545–547
    pain management in, 547–549
    tender points, 546
Fibrosis, radiation, 540
Fifth vital sign, 3, 731, 735
Fiorinal, tension headache and, 557
First pass effect of opioids, 167
Flare
    of pain, in fibromyalgia, 547–548
    of rheumatoid arthritis, 524–525
Flecainide, 318
Flexeril; see Cyclobenzaprine
Flow sheet for pain management, 78–86
Fluid therapy during labor and delivery, 621
Flumazenil, 381
    procedural analgesia with, 385
Fluoxetine, 305
    as adjuvant analgesic, 307
    indications and dosage of, 343
Fluphenazine, 305
Flurazepam, 698, 699
Flurbiprofen, 139
FMS; see Fibromyalgia
Food and Drug Administration pregnancy risk classifications, 609–610, 611
Formulary analgesic reference guide, 737
Fox Chase Cancer Center, 274
Fracture
    osteoporosis and, 573
    rib, fentanyl for, 26
Frail elderly, 700–701
    “Frequent flyer,” 51, 52, 53
Full agonist; see Mu agonist
G
GABA agonist; see Baclofen
GABAergic drug, 305
Gabapentin, 305
    adverse effects of, 323
    for child, 341
    dosage of, 324, 342
    elderly and, 697
    indications for, 342
    neuropathic pain and, 321
    overview of, 322
    patient education about, 350–351
    trial of, 324
Gain, secondary, 41–42
Gallium nitrate, 325
    for bone pain, 325, 326
Gamma-aminobutyric acid, 22–23
Ganglion blockade, 583–584
Gastrointestinal bleeding in elderly, 689–690
Gastrointestinal disorder
    corticosteroid and, 312, 698–699
    Crohn’s disease and, 597–598
    Ehlers-Danlos syndrome and, 543
    elderly and, 679
    harmful effects of pain on, 27–28
    malignant bowel obstruction and, 326–327
    nonsteroidal antiinflammatory drugs and, 130, 135, 136–137
    perioperative bleeding and, 145–146
    opioid withdrawal in infant and, 632
    opioids causing, 261, 262–263
    pancreatitis and, 579–581
    Gastrointestinal surgery in elderly, 678
    Gastroprotective therapy, 137
Gel pack, cold, 409
Gender
    pain assessment and, 57
    pain in infant and, 649–650
General anesthesia, procedural, 386–389
Generic name of nonopioid drugs, 138
Genetic disorder, sickle cell disease as, 585–588
Genitourinary system, effects of pain on, 27
Gingival administration of opioids, 201
Glucocorticoid; see Corticosteroid
Glucose-6-phosphate dehydrogenase deficiency, 376
Glutamate in pain transmission, 22
Gold salts for arthritis, 526
Goody’s Extra Strength, 149
Gout, 690
GR90291, 190
Graphic rating scale, 62–63
Graphic vital signs record, 735
Gross motor movement in infant, 634
Group drug therapy, 446
Growth hormone, 24
Guanethidine, 584
Half-life
definition of, 162
of opioid, 169–170
Hallucination, opioids causing, 263
Hallucinogen, 432
Haloperidol in elderly, 702
Handheld vibrator, 411–412
Harmful effects of pain, 3–4, 23–32, 24
H2-blocker, 131
ulcer prevention and, 137
Head and neck pain
elderly and, 679
mucositis and, 601–602
myofascial, 571
Headache, 550–560
alcohol withdrawal and, 457
assessment of, 550, 552
breast feeding and, 624
caffeine-containing analgesics and, 150
cluster, 555–556, 557–559
description of, 550
diagnosis of, 552, 557, 558
diary about, 551
gel pack for, 409
medications for, 554–556
migraine, 552–556
in child, 143
nonsteroidal antiinflammatory drugs for, 132
postdural puncture, 232
pregnancy and, 615
rebound, 559
tension-type, 555, 557–558
Health care professional
expectations about pain of, 44–46
infant and, 661–663, 668
nondrug treatment and, 402–403
nurse
certification of, 11, 13
expectations about pain of, 44
pain resource, 5
Health care professional—cont’d
nurse—cont’d
role of, 125, 128
undertreatment of pain and, 4–5, 9–10
Heart
antidepressant effects on, 405–411
elderly and, 698
Heart surgery
elderly and, 679
in infant, 662
Heartburn in pregnancy, 616
Heat, 406–411
arthritis and, 526
contrast bathing, 411
fibromyalgia and, 549
patient use of, 410
Hematologic disorder, 135, 138
perioperative, 145–146
Hematoma, epidural, 234–236
Hemodynamics
clonidine and, 336
epidural local anesthetics and, 231
Hemoglobin
elderly and, 690
sickle cell disease and, 585
Hemophilia, 598–599
HIV infection in, 599
nonsteroidal antiinflammatory drugs and, 138, 144
Hepatic impairment
acetaminophen causing, 134–135, 151–152
tramadol and, 191
Heroin, 432
addiction to, 9, 51, 53, 433
Herpes zoster, 561–564
chronic pain and, 31
elderly and, 696
Hip replacement, 252
Histamine blocker
elderly and, 699
nonsteroidal antiinflammatory drugs and, 131
ulcer prevention and, 137
Histoacryl blue, 395
History, analgesic, 123, 124
HIV; see Human immunodeficiency virus
peripheral neuropathy in, 576
Home care
for cancer patient, 542
Ehlers-Danlos syndrome and, 545
for elderly, 683–686
sickle cell disease and, 587
Hormone
osteoporosis and, 575
pain and, 24
Hospice care, 681
creation of, 10–11
Hospice nurse certification, 13
Hospitalization
of elderly, 679–681
musculoskeletal effects of, 28
5HT1 receptor, 553
Human immunodeficiency virus (HIV) infection, 564–568
pain sources and locations, 566
peripheral neuropathy and, 576
Humoral head, aseptic necrosis of, 539
Hurricane; see Benzocaine
Hydrocodone, 116, 134
characteristics of, 179
fixed, 116–117
opioid-nonopioid, 134
equianalgesic dosage of, 133, 240, 241
as fixed combination, 116–117
pregnancy and, 614
Hydromorphone
as addictive drug, 432
bioavailability of, 169
characteristics of, 179, 182–183
elderly and, 691
equianalgesic doses of, 241
intrapspinal, 223, 225–226
mental status change and, 267
nebulized, 203
for opioid-naive adult, 225
patient information about, 279–280
patient-controlled analgesia with, 252
cardiovascular effects of, 25
in child, 255
sickle cell disease and, 587
solubility of, 169
transdermal fentanyl and, 209
Hydrophilic, 162
Hyperalgesia, 429
Hypercoagulation as stress response, 27
Hypersensitivity, aspirin, 144
Hypnosis for burn pain, 531
Hypnotic
as addictive drug, 432
elderly and, 699
Hypotension
antidepressants and, 308
in elderly, 697
labor and, 621
Hypoxemia, in elderly, 701
Hytrin; see Terazocin
I
Iatrogenic risk, 474
Ibuprofen; see Ibuprofen
Ibuprofen
caffeine with, 316
for child, 143
in combination drugs, 134
dosage of, 139
elderly and, 690
gastrointestinal side effects of, 136–137
overdose of, 152
patient information sheet for, 153–154
tension headache and, 557–558
Ibu-Tab; see Ibuprofen
Ileus as stress response, 27–28
Illegal drug, 438–439
Illness Behavior Questionnaire, 519
Imipramine, 305
as adjuvant analgesic, 306–307
for child, 341
indications and dosages of, 343
Imitrex, Sumatriptan
Immune deficiency
chronic fatigue and, 597
fatigue and, 597
HIV infection and, 597
Immune system effects of pain, 29–30
Immunization, 638–639, 638
Immunocompetence, 29
Implantation of electric stimulator, 603
Incisional pain, 409
Indicator, 712
Indinavir, 567
Individualization of analgesic regimen, 121–123
Indocin; see Indomethacin
Indomethacin
bone formation and, 147
dosage of, 139
pediatric, 143, 654
elderly and, 699
Infants, 629–669
abstinence syndrome in, 609
anesthesia dosage, 657
assessment of, 639–640, 649–651
circumcision in, 371, 636–637
consequences of pain in, 631–635
definition of pain in, 628
developmental care, 658
EMLA in, 376
infusion rates, 654
measurement of, 640–649
memory of pain in, 30
misconceptions about, 627
opioid weaning flowsheet, 632
operational definitions, 648
pain during birth in, 635–636
pain management in
algorithm for, 662–663
CRIES measurement score, 646
DSVNI, 646, 647
distress scale for ventilated facial expressions, 633
guidelines, 664–667
health care professional’s role in, 661–663, 668
immunizations, 638
multidimensional assessment, 650
multidimensional measures, 650
minimizing, 661
nonpharmacologic, 658–661
parents’ role in, 667
pharmacologic, 651–658, 656, 657
PIPP, 645
protocol for, 664–667
unidimensional measures, 643
Infants—cont’d
- preterm, 609, 637–638
  - interventions, 662–663
- procedural pain in, 638–639
- respiratory depression, 655
- silent cry, 634
- undertreatment of pain in, 628–631

Infection
- human immunodeficiency virus, 564–568, 566
- intraspinal analgesia and, 234, 235
- Lyme disease and, 600–601
- masking of, 144
- opportunistic, 567
- varicella-zoster, 561–564, 561

Inflammation
- arachnoiditis and, 596
- arthritis causing, 523–525, 524, 525
- Crohn’s disease and, 597–598
- mucositis and, 601–602
- pancreatic, 579–581
- wound pain and, 592–593

Inflammatory mediator, 130

Information, patient/family, 126–127

Infused consent, 365

Infusion
- flow sheet for, 78–82
- intraspinal, 220; see also Intraspinal analgesia
  - lidocaine in, 339, 370–371
- local anesthetic, 317, 320
- needle placement, 211
- of neurotoxic agent, 233
- opioid, 211
  - in opioid naive patient, 250–251
  - subcutaneous continuous, 211, 212–213
- remifentanil, 190

Inhalation, nitrous oxide, 388–389

Initial pain assessment, 59–62

Injections
- fibromyalgia and, 549
- intramuscular, technique for, 391, 392–395
- low back pain and, 600
- nerve block; see Nerve block
  - of neurotoxic agent, 233
  - osteoporosis and, 575
  - painful, 370–371
  - reducing discomfort, 392
- trigger point, 570

Injury
- infant and, 638–639
- needle or catheter, 233
- spinal cord, 606–607
- wound pain and, 592–595

Innovar for labor and delivery, 618

Inpatient
- drug treatment and, 454–456, 461
- Ehlers-Danlos syndrome and, 545
- oral patient-controlled analgesia for, 199
- sickle cell disease and, 587

Institutional barriers to pain management, 713

Institutional commitment to pain management, 715–738; see also Pain management

Institutional needs assessment tool, 724–726

Insulin, 24

Intensity of pain
- initial assessment of, 59
- opioid analgesic and, 191–192

Interaction
- drug-receptor, 165–166, 165, 166, 167
- opioid, 192–193

Intercostal nerve, 535

Interdisciplinary pain care committee, 713, 715–737; see also Pain care committee

International Association for the Study of Pain, 5
- classifications of pain facilities, 514
- clinical practice guidelines of, 7
- education resources of, 6
- founding of, 11
- infants and, 628
- malingering and, 41

International Headache Society, 550, 552

Internet resources, 745–750

Interstitial Cystitis Association, 517

Interviewing, motivational, 446–450

Intestine, Crohn’s disease of, 597–598

Intolerance, aspirin, 144

Intraarterial opioid administration, 196

Intracerebroventricular administration, 196

Intracranial pressure, corticosteroids for, 312

Intractable migraine, 556

Intractable pain treatment act, 9

Intramuscular administration
- avoidance of, 121
- inappropriate, 54
- of opioid, 209–210
- reducing pain of, 391–394
- Z-track, 391, 392

Intranasal administration, 195

Intrapleural analgesia for pancreatitis, 581

Intraoral appliance for temporomandibular dysfunction, 590

Intrathecal analgesia for pancreatitis, 581

Intraspinal analgesia, 213–239; see also Epidural analgesia
- bioavailability and, 220–222
- catheter removal and, 236
- in child, 236–239
- clonidine and, 229, 231
- combined, 231
- complications of, 232–236
- drug delivery and, 214–220
- for elderly, 693–694
- fentanyl and, 225
- guidelines for, 215
- hydromorphone and, 225–227
- labor and delivery and, 619–621
- local anesthetics and, 227–229
- methadone and, 227
Intraspinal analgesia—cont’d
morphine and, 222, 224–225
spinal anatomy and, 213–214, 216–217
use of, 215
Intrathecal administration, 196

Intravenous administration; see also Infusion
lidocaine, 338–339
of opioid, 195

cancer-related pain and, 541
methadone and, 186
oral analgesia after, 258–259
oxymorphone and, 187
for procedural pain, 378, 379
needle placement, 211
patient-controlled; see Patient-controlled analgesia
remifentanil and, 190

Kangaroo care, 660
Kappa opioid receptor site, 166
Ketamine, 305
for crescendo pain, 336–338
neuropathic pain and, 321, 328–330
procedural analgesia with, 386–387, 387

Ketoprofen
dosage of, 139
overdose of, 152

Ketorolac—cont’d
preoperative use of, 133, 144
procedural analgesia with, 380–381
renal function and, 146–147
for surgical patient, 147
in terminally ill patient, 134
Kidney damage from acetaminophen, 135–136
Kindling effect, 433–434
Klonopin; see Clonazepam
Knee replacement, 694

K

Jaw pain, 588–592
JCAHO; see Joint Commission on Accreditation of Health-care Organizations

Joint
arthritis of, 523–525, 524–525
elderly and, 679
temporomandibular, 588–591

Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 3, 730, 733

Journals on pain management, 5, 8, 738

K

Kangaroo care, 660
Kappa opioid receptor site, 166
Ketamine, 305
for crescendo pain, 336–338
neuropathic pain and, 321, 328–330
procedural analgesia with, 386–387, 387

Ketoprofen
dosage of, 139
overdose of, 152

Ketorolac—cont’d
preoperative use of, 133, 144
procedural analgesia with, 380–381
renal function and, 146–147
for surgical patient, 147
in terminally ill patient, 134
Kidney damage from acetaminophen, 135–136
Kindling effect, 433–434
Klonopin; see Clonazepam
Knee replacement, 694

K

LAAM, 443–445
Label
chronic pain and, 492
Labeling
addiction as, 51–52
Labor and delivery, 609–623
benzodiazepines in, 618–619
buprenorphine avoided in, 112
clonidine for, 336
controversies regarding, 621
epidural meperidine ion, 226
lidocaine for, 370
local anesthetics in, 618
nondrug methods during, 617–618
opioids in, 619
pain in infants during, 635–636
parenteral pain relief during, 619
patterns of labor pain, 617
postpartum pain and, 621–622
regional techniques during, 619–621
Laceration, atraumatic suturing of, 395
Lactation, 623–624
AAP classifications, 623
Ladder, WHO analgesic, 115–119, 117

cancer-related pain and, 539, 541
Lamotrigine, 305, 322
adverse effects of, 323

Lancinating pain, 302
adjuvant analgesics for, 109, 320–324
anticonvulsants for, 697
herpes zoster and, 562
Legal issues with placebo use, 55
LET, 373, 374
Levator scapulae trigger point, 571
Levo-alpha-acetylmethadol, 443–445
Levo-Dromoran; see Levorphanol
Levorphanol
characteristics of, 179, 183
elderly and, 692
equianalgesic doses of, 241
Library, pain management, 738

Lidocaine
buffered, 370, 371
bupivacaine with, 368
burn injury and, 530–531
circumcision and, 636–637
cluster headache and, 559
elderly and, 698
Lidocaine—cont’d
in EMLA; see EMLA
infant and, 656
injectable, 368–371
intraspinal, 228
labor and delivery and, 618
migraine and, 555
neuropathic pain and, 318
parenteral, 338–339
for procedural pain, 369
 topical, 331–332, 372
in topical mixtures, 373, 374

Lifestyle in pain assessment, 58

Ligament, round, 615

Limb pain, phantom, 603–604

Limbitrol; see Chlordiazepoxide

Lioesal; see Baclofen

Lipid solubility of opioids, 169

Lipophilic, definition of, 162

Lipophilic opioid
pregnancy and, 614
topical, 201

Listening, active, 416

Lithium for cluster headache, 556

Liver
acetaminophen and, 134–135, 151–152
opioid analgesia and, 192

Local anesthetic; see also Lidocaine
as adjuvant analgesic, 316
adverse effects of, 318–319
for child, 239, 341
topical, 694, 699
epidural
in child, 239
muscle protein synthesis and, 25
unwanted effects of, 230–231, 230
eutectic mixture of; see EMLA
elements of, 305

gastrointestinal function and, 27
guidelines, 367, 369–370
inductions and dosages of, 344
infant and, 656
intraspinal, 227–229
labor and delivery and, 618, 620
low back pain and, 600
mechanism of action of, 318
neuropathic pain and, 317–320
parenteral, 338–339
perioperative/postoperative, 145
pregnancy and, 614
procedural pain and, 367–378
guidelines for, 367
injectable, 368, 370–371
iontophoresis and, 377–378
topical, 371–377
toxicity of, 368

Location of pain, 59

Lodine; see Etodolac
Long-term care facility, 681–683
selection of, 682–683

Loracet, 134

Lorazepam
burn injury and, 529
equisedating doses of, 656
infant and, 655
procedural analgesia and, 381, 385

Lortab; see Hydrocodone

Low back pain, 599–600
Low-birth-weight infant, 627

LSD, addiction to, 433

Ludionil; see Maprotiline

Lumbar epidural analgesia, 222
labor and delivery and, 620

Lumbar plexus pain, cancer-related, 535
Lumbosacral plexus, radiation fibrosis of, 540
Lumbosacral vertebral tumor, 536

Lung cancer, 532
age and, 678

Lyme disease, 600–601

M
Magnesium, migraine and, 553
Magnesium salicylate
bleeding disorder and, 144
dosage of, 139
opioid equivalent, 133
nonprescription brands of, 151

Maintenance stage of drug treatment, 448

Major histocompatibility complex in Crohn’s disease, 597

Malignancy, 531–543; see also Cancer-related pain

Malignant bowel obstruction, 326–327, 327
Malingering, 36, 41

Maprotiline, 305, 306, 307

Marcaine; see Bupivacaine

Marijuana addiction, 432, 433

Masking of infection, 144

Massage, 420–421
fibromyalgia and, 549

Mastectomy, 604

Maternal hypotension in labor, 621

Maternal-placental-fetal drug transfer, 610–611, 613
Maximally Discriminative Facial Coding System, 641

Mayday Pain Resource Center, 6

McGill Pain Questionnaire, 75, 577

Measurement of pain in infant, 639–651, 643

Mechanical ventilation, weaning from, 271–272

Meclofenamate, 139

Meclomen; see Meclofenamate

Mediator, inflammatory, 130

Medical model of addiction, 431–432

Medical record pain management audit, 727

Medication, patient information about, 277–292

Mefenamic acid, 139

Membrane potential, resting, 18

Memory loss, 705

Memory of pain in infant, 630–631

Meningoencephalitis, 562

Menopause, osteoporosis and, 575

Mental disorder, psychogenic pain in, 48–50
Mental status
aging and, 702–704, 704
alcohol withdrawal and, 457
Mini-Mental State examination and, 702, 703
opioids causing change in, 263t, 266–267
pain effects on, 28–29
Mepergan, 618
Meperidine
breast feeding and, 623
characteristics of, 179t, 183–185
elderly and, 692–693
equianalgesic dosages of, 133t, 241t
intraspinal, 223, 226–227
labor and delivery and, 618
misconceptions about, 184t
pancreatitis and, 587
patient-controlled analgesia with, 252t
pregnancy and, 614
procedural analgesia with, 379t, 380
sickle cell disease and, 587
switching from, 255–256
Mepivacaine, intraspinal, 228
Meprobamate in elderly, 699t
Mescaline addiction, 433
Meta-analysis double blind study, 302
Metabolic disorder
fibromyalgia and, 547
opioid withdrawal in infant and, 632
Metabolic effects of pain, 23–25
Metabolism in elderly, 687, 688
Metabolite
definition of, 162
opioid, 169
of morphine, 691
pregnancy and, 614
of remifentanil, 190
Methadone
addiction and, 432t, 433, 443–445
cancer-related pain and, 541
characteristics of, 179t, 185–186
elderly and, 692
equianalgesic doses of, 242t
intraspinal, 227
morphine versus, 186
oral administration of, 185, 185t
pregnancy and, 614
transmucosal of, 201
Methemoglobinemia, EMLA and, 332, 376
Methocarbamol, 305t
elderly and, 700
as muscle relaxant, 327, 328
Methotrimperazine, 305t
dosage of, 334
indications and dosages of, 344
Methylphenidate, 305t
as adjuvant analgesic, 314–315
for child, 341t
indications and dosages of, 344
Methylprednisolone, 305t
Methylsergide
cluster headache and, 556t
migraine and, 555t
Metoclopramide
mechanism of action of, 333
migraine and, 554t
rebound headache and, 559
Mexiletine, 305t
adverse effects of, 318–319
for child, 341t
elderly and, 698
herpes zoster and, 562
indications and dosages of, 344
neuropathic pain and, 318, 321t
patient education about, 352–353t
peripheral neuropathy and, 579
Mexitil; see Mexiletine
M3G, 180–181, 181t
M6G, 180–181, 181t
Midazolam
equisedating doses of, 656t
infant and, 655
morphine with, 335
procedural analgesia and, 381, 385t
Midrin, 554t
Migraine headache, 552–556, 552f
breast feeding and, 624
in child, 143t
Migration, catheter, 233
Millon Clinical Multiaxial Inventory, 519
Miltown; see Meprobamate
Mini-mental state, 703
Minipress; see Prazosin
Minnesota Multiphasic Personality Inventory-2, 519
Misoprostol
elderly and, 690
nonsteroidal antiinflammatory drugs and, 131t
ulcer prevention and, 137
Mitochondria in fibromyalgia, 547
Modified Behavioral Pain Scale, 641
Modulation of pain, 16, 19t
antidepressants and, 309f
definition of, 106f
illustration of, 21, 107f, 319
local anesthetics and, 319f
process of, 22–23
Monitoring
of antidepressant therapy, 311
by pain care committee, 733–734
Monoamine oxidase inhibitor, 183
Mononeuropathy, 19t
Moral model of addiction, 431
Morbidity, 16
Morphine
addiction to, 432t, 433
benzodiazepines with, 335
blood levels of, 181t
buccal administration of, 201
burn injury and, 529t, 530
cancer-related pain and, 541
Morphine—cont’d
characteristics of, 179t, 180–181
dextroamphetamine with, 339
ing elderly, 691
—cognitively impaired, 701, 702
equianalgesic doses of, 241t
gastrointestinal function and, 27–28
immune system and, 29
in infant and, 654–655, 654t, 666
intraspinal, 222–225
intravenous administration of, 211
ketamine with, 338
mental status change and, 267
metabolites of, 169
methadone versus, 186
nebulized, 203
oral, 197–198
patient information about, 281–286t
—procedural analgesia with
in child, 255
—in opioid naive patient, 252t
postoperative, 250–251
pregnancy and, 614
procedural analgesia with, 379t
sickle cell disease and, 587
switching from, 256–257
transdermal fentanyl and, 208–209, 209t
transmucosal administration of, 201
Morphine-3-glucuronide, 691
Morphine-6-glucuronide, 691
Morphine-like drug; see Mu agonist
Mortality, 16
Motivational approaches to drug treatment, 448–450
Motivational interviewing, 446–450
Motor deficit with epidural local anesthetics, 230t
Motor vehicular accident by elderly, 698
Motrin; see Ibuprofen
Mouth
—mucositis and, 601–602
temporomandibular dysfunction and, 588–592
Movement
—pain in infant and, 634
—wound pain and, 593
MPS, 548
Mu agonist; see also Individual drug
agonist-antagonist with, 112
characteristics of, 178–180, 180t
codeine, 181
combination analgesics with, 116
comparison of, 113–114
definition of, 104, 162
examples of, 109t
fentanyl, 181–182
hydrocodone, 182
hydromorphone, 182–183
levorphanol, 183
meperidine, 183–185
methadone, 185–186
morphine, 180–181
Mu agonist—cont’d
—oxycodone, 186–187
—oxymorphone, 187
—propoxyphene, 187–188
titration of, 122
Mu opioid receptor site, 166
Mucosa, gastric, 136
Mucositis, 601–602
Multidimensional Pain Inventory, 519
Multidimensional pain measure for infant, 642–649, 650, 651t
Multidisciplinary pain care program for elderly, 680–681
Multigravida, 609
Multimodal, continuous analgesia; see Balanced analgesia
Multiple sclerosis, 602–603
charting example, 492t
Muscle, temporomandibular dysfunction and, 588–592
Muscle protein synthesis, 25
Muscle relaxant
—elderly and, 700
—examples of, 305t, 327
—misconceptions about, 303t
—osteoforosis and, 574
Musculoskeletal system
—adjuvant analgesics for, 327t
—Ehlers-Danlos syndrome and, 543–545
—fibromyalgia and, 545–550
—gel pack for injury to, 409f
—harmful effects of pain on, 27–28
—postpolio syndrome, 604–605
—tumor of, 533t
Music
—active listening, 416f
—for distraction, 391t, 415, 416f
—in procedural pain management, 390
—for relaxation, 421
Myelopathy, radiation, 540t
Myocardial ischemia, 694
Myoclonus, opioids causing, 266
Myofascial pain, 489
—syndrome, 568–572, 569t
—trigger points, 571f
N
Nabumetone
—bleeding disorder and, 144
dosage of, 140, 140t
Nalbuphine
—characteristics of, 189
—equianalgesic doses of, 242t
—labor and delivery and, 618
—pregnancy and, 614
Nalfon; see Fenoprofen
Nalbuphene
—opiod overdose and, 269
—procedural analgesia with, 379t, 380
Naltrexone
—administration of, 269, 270t
—cancer-related pain and, 541–542
—inappropriate use, 269
—opiod overdose and, 269, 270
Naloxone—cont’d
procedural analgesia with, 379·t, 380
Naltrexone, 460–461
Naprosyn; see Naproxen
Naproxen
dosage of, 139·t
for child, 143·t
overdose of, 152
Naratriptan for migraine, 554·t
Narcotic, definition of, 104, 162, 429; see also Opioid analgesic
Naropin; see Ropivacaine
Nasal spray, 112
National Association of Orthopaedic Nurses, 55
National Hospice Organization, 11
National Institute of Arthritis, Musculoskeletal and Skin Diseases Information Clearinghouse, 517
National Institute of Drug Abuse, 430
National Institutes of Health, 274
National Neurofibromatosis Foundation, Inc., 517
National Vulvodynia Association, 517
Natural childbirth, 609
Natural killer cell, 29
Nausea and vomiting
alcohol withdrawal and, 457
elderly and, 695
ergotamine withdrawal and, 559
migraine and, 553
opioids causing, 261, 262–265, 262·t–263·t
Nebulized opioid, 195·t, 203
Neck pain, myofascial, 571·f
Necrosis, aseptic, 539
Necrotizing enterocolitis, 660
Needle
intraspinal, 214–220, 218·f
complications of, 233
subcutaneous infusion, 211·t
Needs assessment tool, 724–726
Nefazodone, 305·t, 306·f
Neglect of elderly, 706
Nelfinavir, 567
Nembutal; see Pentobarbital
Neonatal abstinence syndrome, 616–617, 631–632
Neonatal facial Coding System, 641
Neonatal Infant Pain Scale, 644–645, 650
Neonatal intensive care unit, 637–638
Neonatal period, 627
Neonate; see also Infant
abstinence syndrome in, 616–617
definition of, 627
EMLA in, 376–377
fentanyl in, 654·t
long-term effects of pain in, 634–635
memory of pain in, 30
morphine in, 654·t
surgery in, opioid for, 24–25
Nerve block
cancer-related pain and, 541
chronic pain and, 510, 511
clonidine, 337·t
herpes zoster and, 563
Nerve block—cont’d
in infants, 657·t
intraspinal opioid versus, 25
local anesthetic for, 367–378; see also Local anesthetic
treatment of, 575
pain, 621
subarachnoid space, 619–620
Nerve block clinic, 11
Nerve fiber, 577
Nerve root, arachnoiditis and, 596
Neuralgia
definition of, 16, 302
postherpetic, 561–564, 561·f
Neuraxial opioid, 621
Neurochemical disorder, 547
Neuroleptic, 332–334
as adjuvant analgesic, 316–317
adverse effects of, 333
effects of, 305·f
indications for, 334
mechanism of action of, 333
Neuroleptic malignant syndrome, 333
Neurologic disorder
Ehlers-Danlos syndrome and, 543
Lyme disease and, 601
migraine and, 553
multiple sclerosis and, 602–603
reflex sympathetic dystrophy and, 581–584
Neurolytic block, celiac plexus, 581
Neuron, afferent, 16
Neuronal “wind-up,” 23
Neurontin; see Gabapentin
Neuropathic pain, 19·t,
adjuvant analgesics for, 109·t, 113
anticonvulsants and, 321–324
antidepressants and, 310, 317, 317·t
lancinating pain and, 320–324, 321·t
local anesthetics and, 317–320
baclofen for, 324
burn injury and, 530
cancer-related, 537, 538·t, 541
classification of, 23
definition of, 16, 162, 675
in elderly, 696, 699·t
anticonvulsants for, 697
herpes zoster and, 563
HIV and, 567
lidocaine for, 338–339
n-methyl-D-aspartate receptor blockers for, 328–330
peripheral, 16, 576–579, 577·f
rating scale for, 75, 76–77
wound, 592
Neurophysiologic adaptation in addiction, 452
Neuropsychologic toxicity of corticosteroid, 312
Neurotensin, 23
Neurotoxic agent, injection of, 233
prevention of intraspinal, 234·t
Neurotransmitter
opioid receptors and, 165–166
Neurotransmitter—cont’d
transmission of pain and, 22
Newborn; see Infant; Neonate
Nifedipine, 305t
Nipple pain, 622
Nitrous oxide
burn injury and, 529t
procedural analgesia with, 387t, 388–389
NMAD; see N-methyl-D-aspartate
NMAD receptor antagonist, 305t
as adjuvant analgesic, 317t
neuropathic pain and, 321t, 328–330
N-methyl-D-aspartate
as adjuvant analgesic, 317t
definition of, 302t
transmission of pain and, 22
Nociceptive pain, 18–23
cancer-related, 533, 537, 541
classification of, 19t
definition of, 16
everly and, 696
intraspinal anesthesia and, 222
modulation of, 21t, 22–23
nonsteroidal antiinflammatory drugs and, 130
perception of, 21t, 22
transduction of, 18, 21f, 22
transmission of, 20t, 21–22, 21f
wound, 592–593, 593t, 594
Nociceptor, 16, 162
Nondrug pain treatments, 399–425
burn injury and, 530–531
for child, 421, 422t
for childbirth, 617
in clinical practice, 421–425
cutaneous stimulation as, 405–417; see also Cutaneous
stimulation
distraction as, 412–417
for elderly, 700
for infant, 658–661
misconceptions about, 401t
relaxation as, 417–421ole of, 400–405
selection of, 404t
Nonmalignant pain
cancer pain versus, 47–48
chronic; see Chronic pain
Nonnarcotic; see Nonopioid analgesic
Nonnutritive sucking, 659
Nonopioid analgesics, 105t; see also Acetaminophen; Aspirin;
Nonsteroidal antiinflammatory drugs
caffeine with, 316
in children, 142–148, 143t
clinical considerations for, 108–110
comparison of, 114t
definition of, 104, 130
dosing information, 133t, 138, 139–140t, 140–143, 142t
for children, 143t
elderly and, 689–691
generic and brand names, 138t
indications for, 131–134, 133t
Nonopioid analgesics—cont’d
infant and, 653–654
mechanism of action of, 130
misconceptions about, 131t
opioid combined with; see Combination analgesic
pain mechanism affected by, 108
perioperative/postoperative, 145
polypharmacy and, 304
selection of, 142t
side effects, 134–138, 135t
titration of, 122
trade and generic names of, 138t
Nonprescription drug; see Over-the-counter drug
Nonsteroidal antiinflammatory drugs (NSAIDs)
for acute versus chronic pain, 138
adverse effects of, 145–148
analgesic action, 132f
analgesic history and, 140
ankylosing spondylitis and, 596
antipyretic effect of, 144
arthritis and, 526
aspirin allergy and, 144
bleeding disorder and, 144
for bone pain, 326
breast feeding and, 142, 623
for child, 142–144
choice of, 110
clinical considerations for, 108–110
combination analgesics with, 116
cost of, 141
definition of, 104, 130
dosages, 139–140t
frequency of, 140–141
guidelines for, 142
titration of, 141–142
drug combinations with, 148–150
everly and, 689–691, 695, 698, 699t
alternative approaches, 690t
cognitively impaired, 704
long-term use, 689t
examples of, 109t
fibromyalgia and, 548–549
gastrointestinal function and, 27
hemophilia and, 599
indications for, 108–110, 131–134, 133t
infant and, 654
mechanism of action of, 130
migraine and, 554t
misconceptions about, 131t
nonprescription, 148–150, 151t
overdose of, 150–152
patient/family teaching about, 152, 153–158, 157–158t
perioperative, 144–148, 146t
metabolic response and, 24
pregnancy and, 142, 611, 613
procedural analgesia with, 380–381
response to, 140
routes of administration for, 110, 141
side effects of, 134–138
temporomandibular dysfunction and, 590
Nonsteroidal antiinflammatory drugs (NSAIDs)—cont’d
transduction of pain and, 18
Norepinephrine, 368
Norflex; see Orphenadrine
Normeperidine, 226
Norpramin; see Desipramine
Norpropoxyphene, 169, 180; 187, 192
North American Chronic Pain Association of Canada, 517
Norpropoxyphene, 169, 180; 187, 192
North American Chronic Pain Association of Canada, 517
Nortriptyline, 305; 306
as adjuvant analgesic, 307
breast feeding and, 623–624
for child, 341
indications and dosages of, 343
patient education about, 348–349
side effects of, 308
tension headache and, 555
Noxious stimulus, 16
NSAIDs; see Nonsteroidal antiinflammatory drugs
Nubain; see Nalbuphine
Nulliparity, 609
Numby Stuff, 377–378
Numerical rating scale, 63
f, 65–75
cultural differences and, 98
definition of, 36
equianalgesic dosage of, 133
t, 174, 240–243
equianalgesic dosage of, 133
examples of, 68f–73f
Numorphain; see Oxymorphone
Nuprin; see Ibuprofen
Nurse
certification of, 11, 13
effects on pain of, 44
pain resource, 5
role of, 125, 128
Nurse-activated dosing, 177
Nurse-based patient-controlled analgesia program, 742–743
Nursing admission assessment, 58
Nursing home, 675, 681–683

O
Obesity, respiratory complications and, 26
Obstetrics/gynecology
Ehlers-Danlos syndrome and, 543
pregnancy and, see Labor and delivery; Pregnancy
Obstruction, bowel, 326–327, 327
Occlusal therapy, 591
Occupational therapy in arthritis, 526
Octreotide
malignant bowel obstruction and, 327, 327
pancreatitis and, 581
Ocular procedure, 372–373
Office of National Drug Control Policy, 431
Ointment, local anesthetic, 332
Older Americans Act, 706
Oncology Nursing Society
education resources of, 6
placebo and, 55, 56
On-line computerized database, 612
Operative site bleeding, 146
Ophthalmic procedure, 372–373
Opiate, definition of, 104; see also Opioid analgesic
Opioid analgesics, 105f, 161–293
for acute pain, 178
addiction to; see Addiction
adverse effects, 146
antidepressant with, 308
around the clock dosing of, 175
in cognitively impaired elderly, 704
rescue dose and, 244–246
arthritis and, 526
breast feeding and, 623
cancer-related pain and, 541; see also Cancer-related pain
cessation of therapy with, 270–271
characteristics of intraspinal, 223–224
in child, 143t–144
for chronic pain, 178t, 496–499
classification of, 165
in combination; see Combination analgesic
definition of, 36, 130, 162, 363, 429
detoxification and, 459
documentation for, 272, 273
dosages, 133
t, starting, 244
rescue, 245
elderly and, 691–695, 694, 699
cognitively impaired, 701
endogenous
composition and function of, 165
definition of, 16
modulation of pain and, 22–23
equianalgesic dosage of, 133, 174, 240–243
examples of, 109
fibromyalgia and, 549
herpes zoster and, 562–563
HIV and, 565, 567
immune system and, 29–30
infant and, 654–656, 654t
weaning flowsheet, 632
intraspinal characteristics, 223–224
labor and delivery and, 618, 619–620
mechanism of action of, 165–166
misconceptions about, 163–164
infant and, 631
potency and, 170
mu agonist characteristics, 179–180
newer, 190–191
nonsteroidal antiinflammatory drug with, 131, 132, 149
oral administration of; see Oral administration, of opioid
osteoporosis and, 574–575
outpatient, 755
pain
mechanism affected by, 108
treatment definitions, 462
pancreatitis and, 581
patient education about, 272–292; see also Education, patient
patient-controlled, 249–255; see also Patient-controlled
analgesia
perioperative, 145
metabolic response and, 24–25
Opioid analgesics—cont’d
peripheral neuropathy and, 578–579
pharmacology of, 166–174
absorption and metabolism and, 168
addiction and, 173; see also Addiction
equianalgesia and, 174
equivalent products, 197
pharmacokinetics of, 167–170
pharmacodynamics of, 170–174
physical dependence and, 173
potency and efficacy and, 170–171
tolerance and, 169–173
polypharmacy and, 304–306
pregnancy and, 613–614
PRN dosing of, 175
for procedural pain, 378–380, 399
receptors; see Opioid receptors
rectal administration of, 205
as rescue analgesia, 134
respiratory effects and, 26
routes of administration of, 195–196
intransal, 203
intraspinal, 213–239; see also Epidural analgesia; Intraspinal analgesia; Intrathecal administration
nebulized, 203
oral, 194–203; see also Oral administration
parenteral, 209–213; see also Intramuscular administration;
Intravenous administration; Subcutaneous administration
rectal, 204–205
stomal, 205–206, 206
transdermal, 206–209
selection guidelines for
agonist-antagonist and, 188–190; see also Agonist-antagonist
mu agonist and, 178–188; see also Mu agonist
new drugs and, 190–191
patient characteristics in, 191–194
route of administration and, 239–240
starting dose and, 240–246
sickle cell disease and, 585, 587
side effects of, 261–270
alternatives for, 256
biliary spasm as, 265
constipation as, 262
epidural analgesia and, 254–255
mental status changes as, 263, 267–268
myoclonus as, 266–267
nausea and vomiting as, 261, 263, 264–265
options for, 256
preventing and managing, 263–264
prevention, 262–264
pruritus as, 263, 265–266
respiratory depression as, 268–270
sedation as, 267–268
urinary retention as, 266
switching of, 257
from epidural to intravenous, 257–259
from multiple drugs to single, 259–260
from one route to another, 257–259
to another opioid, 253, 255–257
temporomandibular dysfunction and, 590
undertreatment of pain and, 9
unwarranted withholding of, 271–272; see also Undertreatment of pain
withdrawal of, 494–496
written agreement about, 753–755
Opioid antagonists, 162, 363; see also Naloxone
inappropriate use of, 269–270
Opioid dose-sparing effect, 130
Opioid-naive patient
epidural analgesia in, 225
infusion and, 81, 251
patient-controlled analgesia for, 250, 252
respiratory depression in, 145, 268–269
tolerant versus, 172–173
Opioid receptors, 165–166, 165f, 166f, 167
Opioid treatment, long term, 490–499, 498
Oral administration
clonidine, 336
of cocaine, 316
of local anesthetic, 317–320
for child, 341
of opioid, 194–201
disadvantages of, 196
formulations for, 196–199
intravenous analgesia and, 258–259
methadone, 185
patient-controlled, 199–200
postoperative pain and, 201
transdermal fentanyl and, 209
transmucosal, 201–203
as optimal route, 121
tramadol and, 190
Oral transmucosal fentanyl citrate, 202
for procedural pain, 378, 379
as rescue analgesic, 245
Organ failure, 192
Organizations, professional, 12
acronyms for, 2
growth of, 11
Orphenadrine, 305
as muscle relaxant, 327, 328
musculoskeletal pain and, 327
nonopioids with, 150
Orthodontic therapy, 591
Orthopedic surgery, 678
Orthostatic hypotension, antidepressant and, 308
in elderly, 697
Orudis; see Ketoprofen
Osteoarthritis, 523–527
affected joints, 525
alternative treatment for, 690
joint characteristics, 524
oxycodone for, 692
Osteoporosis, 572–576
assessment of, 573–574
definition of, 572–573
fracture sites in, 573
pain characteristics of, 573
pain management of, 574–575
Osteoporosis—cont’d
posture in, 574f
Osteoporosis and Related bone Diseases National Resource Center, 518
OTFC; see Oral transmucosal fentanyl citrate
Oucher rating scale, 63
Outpatient
chronic pain and, 505
drug treatment and, 451t, 456, 458
patient information for, 752, 755
Overdose
of nonsteroidal antiinflammatory drugs, 150–152
opioid, 269
Over-the-counter drug
arthritis and, 526
list of, 125
nonopioid, 148–150, 148t–149t, 150t
rebound headache from, 559
Oxaprozin
brand name of, 138t
dosages of, 139t
Oxazepam, 656t
Oxicam, 139t
Oxycodone
characteristics of, 180t, 186–187
elderly and, 692
equianalgesic doses of, 133t, 242t
fixed combination with, 117
oral, 198–199
patient information about, 287–290
pregnancy and, 614
switching from, 259, 260
transdermal fentanyl and, 209t
Oxygen
cluster headache and, 559
cognitive impairment in elderly and, 701
headache and, 556–557
sickle cell disease and, 585
thermoregulation and, 26
Oxymorphone
characteristics of, 180t, 187
equianalgesic doses of, 242t

Pacing, by patient, 504t
Pain—cont’d
centrally generated
classification of, 19t
definition of, 16
chronic; see Chronic pain
classification by inferred pathology, 19t
clinician’s expectations about, 44–46
conditions causing, 522–607
ankylosing spondylitis, 595–596
arachnoiditis, 596
burn, 527–531
chronic fatigue syndrome, 597
Crohn’s disease, 597–598
Ehlers-Danlos syndrome, 543–545
fibromyalgia syndrome, 545–550
headache, 550–560
hemophilia, 598–599
herpes zoster, 561–564
human immunodeficiency virus infection, 564–568
low back pain, 599–600
Lyme disease, 600–601
mastectomy, 537t, 604
mucositis, 601–602
multiple sclerosis, 602–603
myofascial pain syndrome, 568–572
osteoporosis, 572–576
pancreatitis, 579–581
peripheral neuropathy, 576–579
phantom limb, 603–604
poliomyelitis, 604–605
reflex sympathetic dystrophy, 581–584
sickle cell disease, 585–588
spinal cord injury, 606–607
temporomandibular joint disorder, 588–591
thoracotomy, 537t, 605–606
wound pain, 592–595
control record, 87–88t
crescendo, 335–340
deafferentation, 302
definition of, 16–17
denial of, 89, 92
documentation of responses, 459t
facilities, 10–11, 514, 514t
harmful effects of, 23–32, 24t
on cardiovascular system, 25–26
on cognitive function, 28–29
on development, 30
on endocrine and metabolic system, 23–25
on future pain, 30–31
on gastrointestinal system, 27–28
on genitourinary system, 27
on immune system, 29–30
on musculoskeletal system, 27–28
on quality of life, 31–32
on respiratory system, 26–27
in infant, 629–669; see also Infant
intensity, 95t
inventory, 61f, 61t
known versus unknown cause of, 46–48
Pain—cont’d
Knowledge and attitude survey, 728t
management; see Pain management
mechanism of, 16–32
  misconceptions about, 17t
  nonopioids and, 108
myofascial, 489
neuropathic; see Neuropathic pain
nociceptive, 18–23, 19t; see also Nociceptive pain
nondrug treatment of, 399–425; see also Nondrug pain
treatment
nonmalignant; see Chronic pain
pathology, inferred, 19
  in elderly, 675
physiology of, resources about, 17
  in pregnancy, 615–616
procedural, 362–395; see also Procedural pain management
psychogenic, 36, 49–50
rating scales; see Pain rating scales
relief diary, 200
report, 90–91
  resource nurse (PRN), 5, 741t, 742
  dosing, 175
response, acute pain model of, 43–46
  screen, 96t
services, 739–740
  creation of, 11
  somatic, 19t
subjectivity of, 5, 9
supratentorial, 49–50
sympathetically maintained, 330
tabetic, 302
threshold, 42
tolerance, high versus low, 42–43
transmission of, 16, 19t, 20–21f, 22–23
  of antidepressant, 309f
definition of, 106f
  illustration of, 21, 107f
  for local anesthetics, 319f
process of, 22
types of, 17–18, 19t
definitions of, 16
treatment approaches to, 18
undertreatment of; see Under treatment of pain visceral, 19t
Pain care committee, 713, 715–737
  composition of, 716–717
  data collection by, 720–730
  establishment of, 715–716
  ground rules for, 718f
  leadership of, 717
  mission statement of, 717–718, 718t
  problems with, 718–720
  resources for, 717f
  responsibilities of, 730–737
Pain management, 711–742
  audit of, 727
  barriers to, 2–10
Pain management—cont’d
barriers to—cont’d
  health care professionals as, 4–10
  institutional, 713
  lack of accountability and, 3–4
  patient and family as, 10
  information gathering for, 513t
  institutional commitment to, 715–743
  administrative rules and, 738
  assessment standards, 743t
  cause and effect diagram, 722–723f
  clinical pathways and, 738–739
  knowledge and attitude survey, 728t
  library, 738t
  need for change and, 720–730
  needs assessment tool, 724–726t
  nurse-based PCA programs and, 742–743
  pain care committee and, 715–720, 730–737
  pain resource nurse programs and, 742
  pain services and, 739–740
  patient questionnaire, 729t
  quick reference guide, 736t
  role model programs and, 740–742
  misconceptions about, 712–713, 712t
  patient questionnaire about, 729
  patient teaching checklist, 273t
  program for, 515
  progress in, 10–13
  quality improvement, 713–715, 714–715, 716t
    data analysis tools, 721f
    teaching checklist, 273
    team approach to, 89t
  in terminally ill, 272
Pain rating scales; see also Assessment, tool
definition of, 36
  faces, 64–65f, 67f
  failure to obtain, 36, 38
  for infant, 639–649
  neuropathy, 76–77t
  preferred, 37
  selecting, 66t
  teaching use of, 74t
  translations of, 68–73f
Palliation, local anesthetics for, 320
Pamelor; see Nortriptyline
Pamidronate, 325
Panadol, 148t
Pancreatitis, 579–581
  autodigestion, 580f
  pain mechanisms, 580t
Paracervical block, 621
Parafon Forte; see Chlorzoxazone
Paranoia, opioids causing, 263t
Paravertebral sympathetic ganglion blockade, 583–584
Parent of infant, 668
Parenteral administration; see also specific routes
  of ketamine, 337–338
  of ketorolac, 133
  in child, 144
Parenteral administration—cont’d
of ketorolac—cont’d
  postoperative, 145
of lidocaine, 338–339
of local anesthetic, 317–320
of nonsteroidal antiinflammatory drug, 131t
of opioid, 209–213
  labor and delivery and, 619, 621
of phenytoin, 339
Paresthesia, 162, 302
Parkland burn pain management pathway, 529t, 530
Paroxetine, 306t, 307
  indications and dosages of, 343
Paroxysmal
  definition of, 302
  sweats in alcohol withdrawal, 457
Patch
  blood, 232
  fentanyl, 277–278
  local anesthetic, 332
  transdermal, 207–209
Patients
  assistance program for, 194
  as barrier to pain management, 10
  education; see Education, patient
  educational materials, 274t
  information for, 126–127t
  pain relief diary, 200t
  report of pain by, 38–40
  rights of, 13t
  surveying of, 721, 729, 730
Patient-controlled analgesia (PCA), 175–177, 211, 248–253
  for acute pain, 754t
  appropriateness of, 176–177
  breast feeding and, 623
  burn injury and, 529t
  cardiovascular effects and, 25
  with continuous infusion, 251–252
  dosage calculation for, 122, 250t
  pediatric, 255t
  for elderly, 693
    cognitively impaired, 702
  epidural, 220, 224–227, 225t
  hydromorphone for, 265
  initiation in PACU, 252–253
  intraspinal, 220, 224–226
  IV use, 176t, 291–292t
  lidocaine for, 339
  nurse-based program for, 742–743
  opioid-naive adult ranges, 252t
  oral, 199–200, 199t
  patient information about, 291–292
  patient selection for, 176–177
  pediatric, 253, 255t
  procedural, 388
  pump use, 177t, 249t
  respiratory effects and, 26
  side effect reduction, 254–255t
  starting prescription for, 250–252, 250t
  subcutaneous continuous infusion and, 210–213
Patient-controlled analgesia—cont’d
  titration of dose and, 246
  unconventional use of, 177
  written agreement for, 754–755
Patient’s bill of rights, 13t
Paxil; see Paroxetine
PCA; see Patient–controlled analgesia
P4502D6, 181t
Pediatric patient; see Child
Pediodicals, clinical, 738
Penicilin, 305t
Penile block for circumcision, 376
Pentamorphine, 190
Pentazocine
  characteristics of, 189–190
  for elderly, 693, 699t
  equianalgesic dosage of, 133t, 242t
  mild pain and, 191
Pentobarbital
  in elderly, 699t
Peptic ulcer
  corticosteroid causing, 312
  in elderly, 698–699
  for elderly, 689
Perception of pain
  antidepressants and, 309t
  definition of, 106f
  in elderly, 675
  local anesthetics and, 319t
  process of, 22
Percocet, 116, 134
Percogesic Coated, 148t
Perinatal period, 609
  definition of, 627
Periodicals, clinical, 5, 8t, 738
Perioperative analgesia
  for gastrointestinal function and, 28
  for nonsteroidal antiinflammatory drugs for, 133, 144–148
  for adverse effects of, 145–148
  for effectiveness of, 144–145
Pentobarbital
  in elderly, 699t
Perioperative analgesia
  for gastrointestinal function and, 28
  for nonsteroidal antiinflammatory drugs for, 133, 144–148
  for adverse effects of, 145–148
  for effectiveness of, 144–145
opioid, 24–25
Peripheral nerve block; see Nerve block
Peripheral nerve in infant, 635
Peripheral neuropathy, 16, 576–579
  assessment of, 577
  cancer-related, 538t
  description of, 576–577, 577t
  pain management of, 577–579
Peripheral vascular disease, 696
Peripherally generated pain, 19t
Perphenazine, 699t
Persistent vegetative state, 94–95
Phantom limb pain, 603–604
  in elderly, 694
  previous acute pain and, 30
Pharmacodynamics in infant, 652–653
Pharmacokinetics
  HIV and, 567
  infant and, 652–653
  of opioids, 167–170
Pharmacology of opioid analgesic, 166–174; see also Opioid analgesic, pharmacology of equivalent products, 197
Pharmacotherapy for drug abuse, 442–443
Phenacetin
  liver toxicity of, 135
  renal failure caused by, 135
Phenergan, 380
Phenobarbital
  alcohol, 458
  opioids and, 193
Phennixazine, 113
  opioids and, 193
Phenylbutazone, 699
  t
Phentolamine, 584
Phenyltoloxamine citrate, 150
Phenytoin, 305
  adverse effects of, 323
  for child, 341
  for crescendo pain, 339
  indications and dosages of, 342
  for lancinating pain, 324
  neuropathic pain and, 321
  opioids and, 193
  overview of, 321–322
  parenteral, 339
Physical abuse of elderly, 706
Physical appearance in pain assessment, 57
  in infant, 633
  f
Physical dependence
  addiction versus, 434
  definition of, 50, 162, 429
  opioid and, 173
Physical rehabilitation
  chronic pain and, 503, 505
  postoperative, 740
Physical therapy
  ankylosing spondylitis and, 595–596
  arthritis and, 526
  chronic pain and, 503, 505
  Ehlers-Danlos syndrome and, 545
  fibromyalgia and, 549
  reflex sympathetic dystrophy and, 583
  temporomandibular dysfunction and, 591
Physiologic response to pain, 95
  acute pain model and, 45
Physiology of pain, resources about, 17
Pipomide, 305
  dosages of, 344
  indications for, 334, 344
  neuropathic pain and, 321
Pinch-grasp injection technique, 395
PIPP; see Premature Infant Pain Profile
Piroxicam, 139
Placebo(s)
  chronic pain and, 492
  controlled trial, 302
  definition of, 36
  EMLA versus, 376
Placebo(s)—cont’d
  misconceptions about, 54–55
  recommendations about, 55–56
  transdermal fentanyl and, 209
  use of, 56, 57
Placenta, 610
Plasma protein, 169
Platelet, 110, 138, 144
Plexus
  brachial
t  cancer-related pain in, 535
  radiation fibrosis of, 540
  celiac, 581
  lumbar, 535
  lumbosacral, 540
  sacral, 536
Policy on placebo use, 56
Polioymelitis, 604–605
Polymyalgia rheumatica, 696
Polyneuropathy
  definition of, 19
  in elderly, 696
Polypharmacy; see also Combination analgesia
  adjuvant analgesics and, 304
  in elderly, 698–699
  HIV and, 567
  misconceptions about, 105
Ponstel; see Mefenamic acid
Positioning of infant, 658–659
Postchemotherapy pain, 538–539
Postdural puncture headache, 232
Posterior deltoid trigger point, 571
Postherpetic neuralgia, 31, 561–564
  in elderly, 696
Postmastectomy pain, 537, 604
Postnatal age, 649
Postoperative pain
  cesarean section, 622–623
  in child, 143
  dextroamphetamine for, 339
  in elderly, 680, 690–691
  cognitively impaired, 701
  nonsteroidal antiinflammatory drugs for, 133, 143
  opioid and, 191–192
  oral analgesics for, 201
  patient-controlled analgesia for, 250–251, 252–253
  preemptive analgesia and, 120–121
  rehabilitation program for, 680, 740
  transdermal fentanyl for, 209
Postpartum pain, 621–623
Postpolio pain, 604–605
Postradiation pain, 540
Postthoracotomy pain, 605–606
Posttraumatic stress, 468
  burn injury and, 529
  531
Posture, stooped, 574
Potency
  definition of, 162
  of opioid, 170–171
  methadone, 186
Potential action
  definition of, 16
  transduction of pain and, 18
resting, 16, 18
Prazosin, 305
  postmastectomy pain and, 604
Preceptorships, 740, 741
Precontemplation stage of drug treatment, 447–448, 447
Prednisone, 305
  breast feeding and, 624
  cluster headache and, 556
  migraine and, 555
Preemptive analgesia
  advantages of, 120–121
  characteristics of, 174–175
for child, 143–144
  concept of, 174–175
  definition of, 162, 363
  nonsteroidal antiinflammatory drugs for, 133, 145
Pregnancy, 609–623
  acetaminophen and, 611, 613
  adjuvant analgesic in, 614–615
analgesics
  opioid, 613–614
  references and resources, 611–612
  use during, 610, 611–615
  back pain in, 615–616
  Braxton Hicks contractions in, 616
  childbirth pain management and, 617–621
FDA risk classification, 609–610, 611
  headache in, 615
  lactation classifications, 623
  maternal-placental-fetal drug transfer and, 610–611, 613
  misconceptions related to analgesic use, 610
  nonsteroidal antiinflammatory drugs and, 142
  pain management resources, 611
  postpartum pain and, 621–623
  pyrosis in, 616
  round ligament pain in, 615
  sickle cell disease and, 616
  substance abuse and, 616–617
Premature Infant Pain Profile (PIPP), 642, 645, 650; see also
Infants; Preterm infants
Preoperative analgesia, nonsteroidal antiinflammatory drugs for, 145
Preoperative medication, nonsteroidal antiinflammatory drugs for, 133
Prescribing of opioid analgesics, 751–755
Prescription analgesic, list of, 125
Pressure
  on injection site, 394
  intracranial, corticosteroids for, 312
  wound pain and, 593
Preterm infants, 609; see also Infants
  CRIES score, 644
  definition of, 627
  intensive care interventions, 662–663
  minimizing pain in, 661
  opioid in, 655
Preterm infants, 609—cont’d
  pain in, 637–638
  behavior, 635
  management guidelines, 664–667
  PIPP, 645
Prilocaine
  circumcision and, 637
  in EMLA; see EMLA
eutectic mixture, 375
Primary afferent neuron, 16
Primigravida, 609
Primipara, 609
Pruritus, 265–266
  use of antagonists and agonist-antagonists, 265–266
Privileging system, 712
PRN; see Pain resource nurses
Procaine
  elderly and, 698
  infusion of, 339
Procedural pain management, 363–395
  angiography and, 390
  assessment in, 366–367
  barbiturates for, 381, 386
  barriers to, 363
  benzodiazepines for, 381, 385
  burn injury and, 529
  cancer treatment and, 537, 537–539
  chloral hydrate, 386
  conscious sedation, 382–387
  general anesthetics for, 386–389
  goals of, 365
  informed consent and, 365
  intramuscular injection and, 391–395
  iontophoresis, 377–378
  local anesthetics for, 367–378; see also Local anesthetic
  misconceptions about, 364
  need for, 363–365, 365
  nondrug approaches to, 389–390
  opioids for, 378–381
  patient education and, 365–366
  refrigerant sprays, 377
  suturing and, 395
  wound and, 593
Process, definition of, 712
Prochlorperazine, migraine and, 554
Professional education, resources for, 6–7
Professional organization
  acronyms for, 2
  focus on pain, 12
  growth of, 11
Promethazine, 695
Prophylaxis
  migraine and, 553, 556
  for NSAID-induced ulcer, 137
  for perioperative/postoperative pain; see Preemptive analgesia
Propofol
  patient-controlled analgesia with, 388
  procedural analgesia with, 387–388, 387
Propoxyphene
  characteristics of, 187–188
Propoxyphene—cont’d
elderly and, 693, 699t
equianalgesic dosage of, 133t, 242t
pregnancy and, 614
Propranolol, 305t
migraine and, 555t, 556
Proprioceptive receptor, 592
Propionic acid derivative, 139t; see Ibuprofen; Ketoprofen; Naproxen
Propoxyphene, 180t
Prostaglandin
nonsteroidal antiinflammatory drugs and, 130, 136
transduction of pain and, 18
Prostate cancer, 532t
age and, 678t
Protease inhibitor, 567
Protein binding
in elderly, 688, 690
opioids and, 169
Protein synthesis, muscle, 25
Protocol for infant, 664–667
Proxy pain rating, 95
Prozac; see Fluoxetine
Pruritus, opioids causing, 263t, 265–266
Pseudoaddiction, 51, 173–174
Pseudorheumatism, steroid, 312
Psilocybin, 433
Psychiatric disorders
with alcohol addiction, 436–437, 436t, 437t
nonmalignant pain and, 476t
Psychiatric setting, 475–476
Psychogenic pain, 36, 49–50
Psychologic dependence, 51, 173–174
Psychologic factors
chronic pain and, 499
fibromyalgia and, 546–547
herpes zoster and, 562
Lyme disease and, 601
reflex sympathetic dystrophy and, 583
Psychostimulant, 314–317
for child, 341t
typical, 305t
Pelvic nerve block, 621
Pumps
external, 219f
implantable, 219f
for patient-controlled analgesia, 175–177, 249; see also Patient-controlled analgesia
Puncture, dural, 232
Pyranocarboxylic acid, 139t, 140t
Pyrosis, pregnancy and, 616
Q
Quality assurance, 712
Quality improvement, 713–715, 721f
data analysis tools, 721f, 722–723f
data collection, 720–730
definition of, 712
guidelines, 716
pain care committee and, 715, 733–734
Quality of life, 31–32
Quality of pain, 59
Quantitative sensory testing, 577
Questionnaire
barriers, 89, 92, 93
CAGE, 705
coping strategies, 519
McGill pain, 577
patient, 729
Quick reference guide for pain management, 736
R.
Race and culture in pain assessment, 57
Radiation fibrosis, 540t
Radionuclide for malignant bone pain, 325t, 326
Randomized study, 302
Ranitidine
in elderly, 699t
NSAID-induced ulcers and, 137
Rash, herpes zoster, 562
Rating scale for pain, 62–75; see also Pain rating scale
Rebound headache, 559
Receptors, opioid, 165–166, 165f, 166t, 167t
intraspinal anesthesia and, 222
Recovery from addiction, 446, 459–460
Rectal administration
of acetaminophen, 150t
in child, 143t, 150t
of nonsteroidal antiinflammatory drug, 131t
of opioids, 195t, 204–205, 205t
Rectal cancer, 532t
age and, 678t
Reference guide
formulary analgesic, 737
for pain management, 736
Referral
chronic pain and, 513, 516
for drug treatment, 450, 451t
Referred pain, 568–572
Reflex sympathetic dystrophy, 581–584
in elderly, 697
typical, 582f
Refrigerant spray, 377
Refusal of pain treatment, 89, 92
Regional anesthesia in infant, 656
Regional blockade
labor and delivery and, 619
reflex sympathetic dystrophy and, 584
Reglan; see Metoclopramide
Regulation, federal, 9–10
Rehabilitation
chronic pain and, 487–490, 503, 505
postoperative, 740
Relafen; see Nabumetone
Relapse in drug treatment, 436–438, 448
Relaxation technique, 417–421
characteristics of, 419
chronic pain and, 500–501
deep breathing, 420t
Relaxation technique—cont’d
imagining, 420t
indications for, 418–419
labor and delivery and, 617
massage as, 420–421, 421t
music, 391t
patient involvement in, 419–421
research about, 418

Remifentanil
characteristics of, 190
metabolism of, 192

Renal function
acetaminophen and, 135–136
ketorolac and, 146–147
nonsteroidal antiinflammatory drugs and, 138
opioid analgesia and, 192
tramadol and, 191

Repolarization, 16

Rescue analgesic
dosage calculation for, 122, 244–246
nonopioids versus opioids as, 134
selection of, 121

Research, terminology related to, 302

Residential drug treatment, 446

Respiratory depression, 264t, 267, 268–270
elderly and, 695

Respiratory effects of pain, 26–27

Respiratory rate, infusion and, 81

Responsiveness
to adjuvant analgesic, 304
to opioid, 171

Resting potential, 16

Restraint of infant, 659

Retention, urinary, 266
epidural analgesia in child and, 239

ReveX; see Nalmefene

Rhenium-186, 325, 326

Rheumatoid arthritis, 523–525
affected joints, 525f
alternative treatment for, 690t
joint characteristics, 524f

Rhinoplasty, gel pack for, 409f

Rib fracture, fentanyl for, 26

Rib pain, cancer-related, 535t

Rid-a-Pain with Codeine, 149t

Rights, of patients with pain, 13, 13t

Rimadyl; see Carprofen

Ritalin; see Methylphenidate

Robaxin; see Methocarbamol

Role model program, 740–742

Ropivacaine
in elderly, 694
injectable, 368
intraspinal, 228
for procedural pain, 369t

Round ligament pain, 615

Route of administration, 131t, 194, 195–196t
adjuvant analgesic and, 113
benzodiazepines and, 381
bioavailability of drug and, 169
buccal, 195t, 201
for elderly, 693–694
epidural, 213–239
individualization of regimen and, 121
infusion; see Infusion
intraarterial, 196t
intracerebroventricular, 196t
intramuscular; see Intramuscular administration
intranasal, 195t, 203
definition of, 162
effectiveness of, 25
midazolam and, 381
intrathecal, 196t, 213–239
for labor and delivery, 619–620
intraspinal, 213–239
intravenous; see Intravenous administration
nebulized, 203
for nonsteroidal antiinflammatory drugs, 110, 141
oral, 194–201
oral transmucosal, 201–203
patient’s resistance to, 54
for procedural pain, 378
rectal, 204–205, 205t
reducing pain in, 391–394
stomal, 205–206
subcutaneous, 195t, 210–211, 211t, 212
sublingual, 195t, 201
switching of, 257–260
systemic, 302
transdermal, 206–209
transmucosal; see Transmucosal administration of opioid
vaginal, 206

Rufen; see Ibuprofen

Rule, administrative, 738

S
Sacral plexus, 536t

Salicylate
dosage of, 139t
overdose of, 152

Saline, bacteriostatic, 370

Saliva, artificial, 602

Salsalate
bleeding disorder and, 144
dosage of, 139t

Samarium-153, 325, 326

Sandostatin; see Octreotide

Sansert; see Methylsergide

Saquinavir, 567
Scaleni trigger point, 571f
Schizophrenia, alcohol addiction and, 436
Sclerosis, multiple, 602–603
Scopolamine, 327
Secobarbital, 699f
Secomal; see Secobarbital
Secondary gain, 41–42
Sedation
conscious, 382–384t
elderly and, 695
infusion and, 81
levels of, 267
misconceptions about, 364
opioids causing, 193, 267–268
procedural analgesia and, 378, 380, 381–386
procedures requiring, 365t
scale, 267f
Sedatives
addiction to, 432t, 433
alcohol withdrawal and, 458
detoxification protocols, 458f
everly and, 699f
infant and, 655
Seizure, tramadol and, 191
Selective serotonin reuptake inhibitor
as adjuvant analgesic, 307, 310
everly and, 697
fibromyalgia and, 548
peripheral neuropathy and, 578
pregnancy and, 614
sexual dysfunction caused by, 309
side effects of, 308
Sensorcaine; see Bupivacaine
Sensory deficit with epidural anesthesia, 230t
Sensory testing, quantitative, 577
Sequential trial, 162, 302
Serotonin, 23
Serotonin antagonist, 555f
Serotonin-receptor agonist, 553
Sertraline, 305f, 306f
indications and dosages of, 343t
Sex hormone in osteoporosis, 575
Sexual dysfunction with antidepressant, 309
Shingles, 561–564, 561f
chronic pain and, 31
Shooting pain; see Lancinating pain
Sickle cell disease, 585–588
pain examples, 586f
pregnancy and, 616
Sickness Impact Profile, 519
Side effects, of opioids analgesics, 261–270
biliary spasm as, 265
constipation as, 262
mental status changes as, 263, 267–268
myoclonus as, 266–267
nausea and vomiting as, 261, 263, 264–265
options for, 256f
pruritus as, 263, 265–266
respiratory depression as, 268–270
sedation as, 267–268
Side effects, of opioids analgesics—cont’d
urinary retention as, 266
Silent cry, 634f
Simple descriptor rating scale, 63
umerical scale versus, 65
Sinequian; see Doxepin
Single blind study, 302
Skin
burn injury to, 527–531
cutaneous stimulation and, 390, 405–412
heat and cold for, 406–411
sites in, 406f
vibration as, 411–412
Ehlers-Danlos syndrome and, 543
shingles and, 561–564
wound pain and, 592–595
Skin-to-skin intervention, 660–661
Sleep disorder
burn injury and, 529f
chronic pain and, 500
in cognitively impaired elderly, 701
pain effects on, 29
severe pain and, 46
wound pain and, 592
Sodium bicarbonate for infant, 665–666
Sodium ion in transduction of pain, 18
Sodium salicylate, 133t
Solubility
intraspinal anesthesia and, 220–222
of opioids, 169
Soma; see Carisoprodol
Somatic pain, 16
cancer-related, 533
definition of, 19f
Somatization, 468
Somatoform disorder, 36, 49
Spasm
fibromyalgia and, 547–548
pain causing, 28
Specialist, certification of, 11–12
Sphincter of Oddi, 581
Spinal analgesia; see also Epidural analgesia; Intraspinal analgesia
clonidine, 337f
Spinal cord
compression of
cancer-related, 539
corticosteroids for, 312, 313, 339–340
injury to, 606–607
neuropathic pain and, 23
pain in infants and, 635
tumor of, 536f
Spinal nerve, dermatomes and, 217f
Spine; see also Back pain
anatomy of, 213–214, 216f
ankylosing spondylitis and, 595–596
arachnoiditis and, 596
elderly and, 679f
osteoporosis and, 574
Spine—cont’d
  tumor of, 533
  vertical column, 216
Spray
  nasal, 112
  refrigerant, 377
Spray and stretch technique for myofascial pain syndrome, 570
Stadol; see Butorphanol
Stanback, 149
Stanback AF Extra-Strength, 148
Standard
  for assessment, treatment, and documentation, 730, 734
  definition of, 712
State medical board, 9–10
Status migraine, 556
Steady state of opioid, 169–170
Steroid; see Corticosteroid
Stiffness, fibromyalgia and, 548
Stigma of addiction, 51, 53
Stimulation
  cutaneous, 390, 405–412
  heat and cold for, 406–411
  sites in, 406
  vibration as, 411–412
  dorsal column, 584
  electric, in multiple sclerosis, 603
Stimulus, noxious, 16
Stoking-glove distribution of pain, 577
Stomach disorder, 136–137
Stomal administration of opioid, 205–206, 206
Stomatitis, 601–602
Stress, 23–32
  chronic pain and, 501–503
  harmful effects of, 23–32
    on cardiovascular system, 25–26
    on cognitive function, 28–29
    developmental effects of, 30
    on endocrine and metabolic system, 23–25
      in future, 30–31
    on gastrointestinal system, 27–28
    on genitourinary system, 27
    on immune system, 29–30
    on musculoskeletal system, 27–28
    on quality of life, 31–32
    on respiratory system, 26–27
  hypercoagulation and, 25
  infant and, 635
  posttraumatic, 468
Stroke, pain after, 696
Strontium chloride-89, 325, 326
Stump pain in elderly, 694
Subacute overdose, 269
Subarachnoid space, 213–214
Subarachnoid space block, 619–620
Subcutaneous administration of opioid, 195, 210–211, 211
  Sublimaze; see Fentanyl
  Sublingual administration of opioids, 195, 201
  Suboccipital trigger point, 571
  Substance abuse, 428–462; see also Addiction
    costs, 441
    diagnostic criteria for, 435, 436
    motivational tasks, 447
    patient placement, 451
    pregnancy and, 616–617
  Substance R, 22
  Sucking, nonnutritive, 659
  Sucralfate, 137
  Sucrose for infant, 659–660
  Sufentanil
    intranasal, 203
    intraspinal, 224, 227
    for opioid-naive adult, 225
    pregnancy and, 614
    solubility of, 169
  Suicide, risk assessment, 487, 487
  Sulindac, 139
  Sumatriptan
    breast feeding and, 624
    cluster headache and, 555
    migraine and, 553
  Superficial heat and cold, 406–411
  Superior vena cava syndrome, 312, 313, 339
  Support group, 686
  Suppository; see Rectal administration
  Supraspinal injection, 162
  Supraspinatus trigger point, 571
  Supratentorial pain, 36, 49–50
  Surgery; see also Perioperative analgesia; Postoperative pain
    ambulatory, 145
    ankylosing spondylitis and, 596
    arthritis and, 526
    gel pack for incisional pain, 409
    in infant, 24–25, 639, 662, 663
    low back pain and, 600
    multiple sclerosis and, 603
    postmastectomy pain and, 604
    reflex sympathetic dystrophy and, 584
    temporomandibular dysfunction and, 591
  Survey
    “Andrew-Robert,” 38, 39–40, 40, 44
    chronic pain and, 508
    pain knowledge and attitude, 729
  Suturing, atraumatic, 395
  Swaddling of infant, 659
  Sweats with alcohol withdrawal, 457
  Sympathetic blockade, 584
  Sympathetic dystrophy, reflex, 581–584, 582
  Symptom Checklist-90R, 519
  Synapse, 16
  Systemic drug, 302

T
  Tabetic pain, 302
  TAC, 373
  Tachycardia, 694
  Tactile disturbance in alcohol withdrawal, 457
  Talwin; see Pentazocine
Tapering of opioid, 270–271, 494–496
Teaching; see Education entries
Temporal arteritis, 695–696
Temporomandibular joint disorder, 588–591
Tegretol; see Carbamazepine
Tension headache, 555, 557–558
Teratogenesis, 609
Tenderness in fibromyalgia, 547
Tenormin; see Atenolol
Tepidol, 148
Tendinitis, 690
Terazocin, 604
Term infant; see also Infant
terminology, 756–757
Testosterone, 24
Tetracaine, 371–372, 373, 374
Tetrahydrocannabinol, 334
Thermoregulation, 26
Thoracic epidural analgesia, 222
Thoracic surgery
in elderly, 678
pain of, 605–606
Thoracic trauma, 26
Thoracic vertebral tumor, 536
Thorazine; see Chlorpromazine
Throat, gel pack for, 409f
Tick-borne disease, 600–601
Tissue adhesive, 395
Titration of dose
for acetaminophen, 141
definition of, 36
individualization of regimen and, 121–122
for nonsteroidal antiinflammatory drugs, 141
for opioid, 246–249
for elderly, 695
patient-controlled analgesia, 253
Tizanidine, 305, 342
TLC, 373
Tocainide, 305
elderly and, 698
indications and dosages of, 344
neuropathic pain and, 318, 321
Tofanil; see Imipramine
Tolerance—cont’d
drug—cont’d
misconceptions about, 163
opioid, 171–173
switching of drug in, 253–257
pain, high versus low, 42–43
Tolmetin, 139
Tonocard; see Tocainide
Tool, assessment, 58–99; see also Assessment, tools for
Topical agent, 331–332, 331
adjvant, 305
antiinflammatory, 331
burn injury and, 530–531
capsaicin, 331
herpes zoster and, 562
infant and, 656–657
local anesthetic, 331–332, 371–377
mucositis and, 602
neuropathic pain and, 321
osteoporosis and, 575
peripheral neuropathy and, 578
refrigerant spray and, 377
Toradol; see Ketorolac
Total body surface area, 527
Total knee replacement, 694
Total quality management, 713, 714–715
Toxicity
corticosteroid, 312
in elderly, 697–698
epidural local anesthetics and, 230
local anesthetic, 318, 368
elderly and, 698
of topical agent, 332
Toxicology, urine, 446
Trade name of nonopioid drugs, 138
Tramadol
characteristics of, 190–191
elderly and, 692
Transcutaneous electrical nerve stimulation
for elderly, 700
reflex sympathetic dystrophy and, 583
Transdermal administration of opioid, 206–209
Transduction, 16, 18, 22
of antidepressant, 309
definition of, 106
illustration of, 21, 107
for local anesthetics, 319
nonsteroidal antiinflammatory drugs and, 130
Transmission of pain, 16, 19
of antidepressant, 309
definition of, 106
illustration of, 21, 107
for local anesthetics, 319
process of, 22
Transmucosal administration of opioid
buccal, 201
characteristics of, 195
of fentanyl, 202, 207, 209
characteristics of, 202–203
Transmucosal administration of opioid—cont’d
of fentanyl—cont’d
for procedural pain, 378, 379t
as rescue analgesic, 245
gingival, 201
for procedural pain, 378
sublingual, 201

Trauma
infant and, 638–639
needle or catheter, 233
spinal cord, 606–607
wound pain and, 592–595

Trazodone, 305

Treatment, misconceptions affecting, 37

Tremor in alcohol withdrawal, 457

Trial, clinical, types of, 302

Triavil, 699

Tricyclic antidepressant; see Antidepressant

Trigeminal Neuralgia Association, 518

Trigger for migraine, 553

Trigger point, 569, 570, 571f
in fibromyalgia
identification of, 546
injection of, 549

Trilisate; see Choline magnesium trisalicylate

Trimester of pregnancy, 609

Trunk pain in elderly, 679

Trigeminal Neuralgia Association, 518

Trigger for migraine, 553

Trigger point, 569, 570, 571f
in fibromyalgia
identification of, 546
injection of, 549

Trilisate; see Choline magnesium trisalicylate

Trimester of pregnancy, 609

Trunk pain in elderly, 679

Tumor, 531–543; see also Cancer-related pain

Twelve-step program of drug treatment, 442–443, 442t
Tylenol; see Acetaminophen

Tylenol 3, 117, 134

Tylox, 117, 134

U

Ulcer
aphthous, HIV and, 566–567
corticosteroid causing, 312
in elderly, 689, 689–699
nonsteroidal antiinflammatory drugs causing, 136, 137
reducing risk of, 110
venous, 592

Unconscious patient, pain assessment in, 94

Undertreatment of pain
in chronic nonmalignant pain, 271
circumcision and, 636–639
diagnosis of cause of pain and, 47
in elderly, 676–677
health care professional and, 4–5, 9–10
education for, 734, 736–737
in infants, 628–631
nurses’ expectations about pain of, 44
postoperative, in child, 144
in terminally ill patient, 272
weaning from mechanical ventilation and, 271–272

Unidimensional pain measures in infants, 640–642, 643t

UNIPACS, 6

Unrelieved pain, 3–4, 23–32, 24t

Urecholine; see Bethanechol

Urethral catheterization, atraumatic, 372t

Urinary retention, 266

Urinary retention—cont’d
epidural analgesia and, 230t
in child, 239

Urine toxicology, 446

Urologic surgery in elderly, 678

Uterus
cesarean section and, 622–623
involution of, 609

V

Vaginal administration
of opioid, 206
of opioids, 195t

Valium; see Diazepam

Valproate
indications and dosages of, 342t
neuropathic pain and, 321t

Valproic acid, 305t
adverse effects of, 323
for child, 341t
cluster headache and, 556t
migraine and, 555t
overview of, 322

Vanquish, 149t

Varicella-zoster virus, 561–564, 561f

VAS; see Visual analog scale

Vascular disease in elderly, 696

Vascular surgery
in elderly, 678t
hypercoagulability and, 25–26

Vasa lateralis injection site, 392f

Vena cava syndrome, superior, 312
corticosteroids for, 312, 313, 339

Venlafaxine, 305t, 306t

Venous ulcer, 592

Ventilation, mechanical, weaning from, 271–272

Ventricular injection site, 392f

Versed; see Midazolam

Vertebral column, anatomy of, 213–214, 216f

Vertebral fracture, 574

Vertebral tumor, 536t

Very-low-birth-weight infant, 627

Vicodin, 117, 134

Vicoprofen, 134

Video tapes pain management, 738

Viracept; see Nelfinavir

Verapamil
cluster headache and, 556t
migraine and, 555t

Versed; see Midazolam

Vertebral column, anatomy of, 213–214, 216f

Vertebral fracture, 574

Vertebral tumor, 536t

Very-low-birth-weight infant, 627

Vicodin, 117, 134

Vicoprofen, 134

Video tapes pain management, 738

Viracept; see Nelfinavir

Viral infection
HIV, 564–568, 566f
peripheral neuropathy in, 576
varicella-zoster, 561–564, 561f

Visceral pain, 16
cancer-related, 534t
definition of, 19t

Visual analog scale (VAS), 62
definition of, 36
Visual analog scale (VAS)—cont’d
horizontal, 62f
numerical scale versus, 65–66
Visual disturbance in alcohol withdrawal, 457
Vital sign
fifth, 3
graphic record of, 735
infant and, 633
Vitamin D, osteoporosis and, 575
Vomiting
alcohol withdrawal and, 457
elderly and, 695
ergotamine withdrawal and, 559
migraine and, 553
opioids causing, 261, 262t–263t
W
Weaning
from mechanical ventilation, 271–272
from morphine in burn injury, 530
from opioid in infant, 632
Web sites
for addiction treatment, 462–463
health-related, 749–750f
Whipple procedure, 258–259
WHO analgesic ladder, 115–119, 117f, 539, 541
Wigraine; see Ergotamine
Williams & Wilkins Complete Library on Pain, 6
Wisconsin Cancer Pain Initiative, 6, 11, 274
Withdrawal
alcohol, 457
chronic pain and, 494–496
corticosteroid, 312
infant and, 631
Withholding of treatment; see also Undertreatment of pain
in chronic nonmalignant pain, 271
opioid, 271–272
in terminally ill patient, 272
weaning from mechanical ventilation and, 271–272
Wong-Baker faces pain rating scale, 63, 66, 67
cultural differences and, 98
World Health Organization
analgesic ladder, 115–119, 117f, 539, 541
Cancer Pain Relief published by, 5
clinical practice guidelines of, 7
Wound pain, 592–595, 593t
Written agreement, 751–755
Z
Zantac; see Ranitidine
Zorgm; see Zolmitriptan
Zolmitriptan, 554f
Zoster ophthalmicus, 562
Z-track method of intramuscular injection, 391–394, 394f